{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:15:11Z","timestamp":1792458911690,"version":"4.5.0"},"reference-count":213,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32400583"],"award-info":[{"award-number":["32400583"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32450786"],"award-info":[{"award-number":["32450786"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Tongji Hospital Clinical Research Flagship Program Funding","award":["2019CR206"],"award-info":[{"award-number":["2019CR206"]}]},{"name":"Tongji Hospital High-Quality Clinical Research Funding","award":["2024TJCR008"],"award-info":[{"award-number":["2024TJCR008"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflamm. Res."],"DOI":"10.1007\/s00011-026-02279-6","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T08:08:35Z","timestamp":1780906115000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Targeting FcRn for immunomodulation: a promising therapy in autoimmune inflammatory rheumatic diseases"],"prefix":"10.1007","volume":"75","author":[{"given":"Peixuan","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaozhe","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingli","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"issue":"3","key":"2279_CR1","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1097\/BOR.0000000000000594","volume":"31","author":"E Liu","year":"2019","unstructured":"Liu E, Perl A. Pathogenesis and treatment of autoimmune rheumatic diseases. Curr Opin Rheumatol. 2019;31(3):307\u201315. https:\/\/doi.org\/10.1097\/BOR.0000000000000594.","journal-title":"Curr Opin Rheumatol"},{"issue":"1","key":"2279_CR2","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/imr.13404","volume":"328","author":"M Hematianlarki","year":"2024","unstructured":"Hematianlarki M, Nimmerjahn F. Immunomodulatory and anti-inflammatory properties of immunoglobulin G antibodies. Immunol Rev. 2024;328(1):372\u201386. https:\/\/doi.org\/10.1111\/imr.13404.","journal-title":"Immunol Rev"},{"issue":"1","key":"2279_CR3","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1136\/ard-2022-223358","volume":"82","author":"SA Bergstra","year":"2023","unstructured":"Bergstra SA, Sepriano A, Kerschbaumer A, van der Heijde D, Caporali R, Edwards CJ, et al. Efficacy, duration of use and safety of glucocorticoids: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2023;82(1):81\u201394. https:\/\/doi.org\/10.1136\/ard-2022-223358.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"2279_CR4","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1002\/bcp.70054","volume":"91","author":"S Park","year":"2025","unstructured":"Park S, Lee AY, Jeong J, Heo KN, Han JM, Ah YM, et al. Incidence and spectrum of typical complications associated with immunosuppressant use in rheumatic disease: a nationwide retrospective study. Br J Clin Pharmacol. 2025;91(8):2420\u201330. https:\/\/doi.org\/10.1002\/bcp.70054.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"2279_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmrv.2023.150767","volume":"38","author":"P Mina-Osorio","year":"2024","unstructured":"Mina-Osorio P, Tran MH, Habib AA. Therapeutic plasma exchange versus FcRn inhibition in autoimmune disease. Transfus Med Rev. 2024;38(1):150767. https:\/\/doi.org\/10.1016\/j.tmrv.2023.150767.","journal-title":"Transfus Med Rev"},{"issue":"1","key":"2279_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/antib12010020","volume":"12","author":"T Velikova","year":"2023","unstructured":"Velikova T, Sekulovski M, Bogdanova S, Vasilev G, Peshevska-Sekulovska M, Miteva D, et al. Intravenous immunoglobulins as immunomodulators in autoimmune diseases and reproductive medicine. Antibodies. 2023;12(1):20. https:\/\/doi.org\/10.3390\/antib12010020.","journal-title":"Antibodies"},{"issue":"4","key":"2279_CR7","doi-asserted-by":"publisher","first-page":"344","DOI":"10.18553\/jmcp.2018.24.4.344","volume":"24","author":"V Strand","year":"2018","unstructured":"Strand V, Tundia N, Song Y, Macaulay D, Fuldeore M. Economic burden of patients with inadequate response to targeted immunomodulators for rheumatoid arthritis. J Manag Care Spec Pharm. 2018;24(4):344\u201352. https:\/\/doi.org\/10.18553\/jmcp.2018.24.4.344.","journal-title":"J Manag Care Spec Pharm"},{"issue":"5","key":"2279_CR8","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1080\/19420862.2019.1602459","volume":"11","author":"DK Challa","year":"2019","unstructured":"Challa DK, Wang X, Montoyo HP, Velmurugan R, Ober RJ, Ward ES. Neonatal Fc receptor expression in macrophages is indispensable for IgG homeostasis. MAbs. 2019;11(5):848\u201360. https:\/\/doi.org\/10.1080\/19420862.2019.1602459.","journal-title":"MAbs"},{"issue":"8","key":"2279_CR9","doi-asserted-by":"publisher","first-page":"2788","DOI":"10.1073\/pnas.0810796106","volume":"106","author":"HP Montoyo","year":"2009","unstructured":"Montoyo HP, Vaccaro C, Hafner M, Ober RJ, Mueller W, Ward ES. Conditional deletion of the MHC class I-related receptor FcRn reveals the sites of IgG homeostasis in mice. Proc Natl Acad Sci U S A. 2009;106(8):2788\u201393. https:\/\/doi.org\/10.1073\/pnas.0810796106.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"2279_CR10","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1084\/jem.180.6.2377","volume":"180","author":"CM Story","year":"1994","unstructured":"Story CM, Mikulska JE, Simister NE. A Major Histocompatibility complex class I-like Fc receptor cloned from human placenta: possible role in transfer of immunoglobulin G from mother to fetus. J Exp Med. 1994;180(6):2377\u201381. https:\/\/doi.org\/10.1084\/jem.180.6.2377.","journal-title":"J Exp Med"},{"issue":"7","key":"2279_CR11","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1002\/eji.1830260718","volume":"26","author":"NE Simister","year":"1996","unstructured":"Simister NE, Story CM, Chen HL, Hunt JS. An IgG-transporting Fc receptor expressed in the syncytiotrophoblast of human placenta. Eur J Immunol. 1996;26(7):1527\u201331. https:\/\/doi.org\/10.1002\/eji.1830260718.","journal-title":"Eur J Immunol"},{"issue":"10","key":"2279_CR12","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1182\/blood-2006-05-024539","volume":"108","author":"G Vidarsson","year":"2006","unstructured":"Vidarsson G, Stemerding AM, Stapleton NM, Spliethoff SE, Janssen H, Rebers FE, et al. FcRn: an IgG receptor on phagocytes with a novel role in phagocytosis. Blood. 2006;108(10):3573\u20139. https:\/\/doi.org\/10.1182\/blood-2006-05-024539.","journal-title":"Blood"},{"key":"2279_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00408","author":"K Baker","year":"2014","unstructured":"Baker K, Rath T, Pyzik M, Blumberg RS. The role of FcRn in antigen presentation. Front Immunol. 2014. https:\/\/doi.org\/10.3389\/fimmu.2014.00408.","journal-title":"Front Immunol"},{"issue":"24","key":"2279_CR14","doi-asserted-by":"publisher","first-page":"9927","DOI":"10.1073\/pnas.1019037108","volume":"108","author":"K Baker","year":"2011","unstructured":"Baker K, Qiao SW, Kuo TT, Aveson VG, Platzer B, Andersen JT, et al. Neonatal Fc receptor for IgG (FcRn) regulates cross-presentation of IgG immune complexes by CD8\u2212CD11b+ dendritic cells. Proc Natl Acad Sci U S A. 2011;108(24):9927\u201332. https:\/\/doi.org\/10.1073\/pnas.1019037108.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"27","key":"2279_CR15","doi-asserted-by":"publisher","first-page":"9337","DOI":"10.1073\/pnas.0801717105","volume":"105","author":"SW Qiao","year":"2008","unstructured":"Qiao SW, Kobayashi K, Johansen FE, Sollid LM, Andersen JT, Milford E, et al. Dependence of antibody-mediated presentation of antigen on FcRn. Proc Natl Acad Sci U S A. 2008;105(27):9337\u201342. https:\/\/doi.org\/10.1073\/pnas.0801717105.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"2279_CR16","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20200359","volume":"217","author":"JJ Hubbard","year":"2020","unstructured":"Hubbard JJ, Pyzik M, Rath T, Kozicky LK, Sand KMK, Gandhi AK, et al. FcRn is a CD32a coreceptor that determines susceptibility to IgG immune complex-driven autoimmunity. J Exp Med. 2020;217(10):e20200359. https:\/\/doi.org\/10.1084\/jem.20200359.","journal-title":"J Exp Med"},{"issue":"23","key":"2279_CR17","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1182\/blood.2019001133","volume":"135","author":"DB Cines","year":"2020","unstructured":"Cines DB, Zaitsev S, Rauova L, Rux AH, Stepanova V, Krishnaswamy S, et al. FcRn augments induction of tissue factor activity by IgG-containing immune complexes. Blood. 2020;135(23):2085\u201393. https:\/\/doi.org\/10.1182\/blood.2019001133.","journal-title":"Blood"},{"issue":"12","key":"2279_CR18","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aax9586","volume":"5","author":"LJ Blumberg","year":"2019","unstructured":"Blumberg LJ, Humphries JE, Jones SD, Pearce LB, Holgate R, Hearn A, et al. Blocking FcRn in humans reduces circulating IgG levels and inhibits IgG immune complex\u2013mediated immune responses. Sci Adv. 2019;5(12):eaax9586. https:\/\/doi.org\/10.1126\/sciadv.aax9586.","journal-title":"Sci Adv"},{"issue":"5","key":"2279_CR19","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1111\/trf.16341","volume":"61","author":"SL Wyckoff","year":"2021","unstructured":"Wyckoff SL, Hudson KE. Targeting the neonatal Fc receptor (FcRn) to treat autoimmune diseases and maternal-fetal immune cytopenias. Transfusion (Paris). 2021;61(5):1350\u20134. https:\/\/doi.org\/10.1111\/trf.16341.","journal-title":"Transfusion (Paris)"},{"issue":"5","key":"2279_CR20","doi-asserted-by":"publisher","first-page":"498.e1","DOI":"10.1016\/j.ajog.2019.02.058","volume":"220","author":"S Roy","year":"2019","unstructured":"Roy S, Nanovskaya T, Patrikeeva S, Cochran E, Parge V, Guess J, et al. M281, an anti-FcRn antibody, inhibits IgG transfer in a human ex\u00a0vivo placental perfusion model. Am J Obstet Gynecol. 2019;220(5):498.e1-498.e9. https:\/\/doi.org\/10.1016\/j.ajog.2019.02.058.","journal-title":"Am J Obstet Gynecol"},{"issue":"6","key":"2279_CR21","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001061","volume":"8","author":"A Garc\u00eda-Serra","year":"2021","unstructured":"Garc\u00eda-Serra A, Radosevic M, R\u00edos J, Aguilar E, Maudes E, Landa J, et al. Blocking placental class G immunoglobulin transfer prevents NMDA receptor antibody effects in newborn mice. Neurol Neuroimmunol Neuroinflamm. 2021;8(6):e1061. https:\/\/doi.org\/10.1212\/NXI.0000000000001061.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"18","key":"2279_CR22","doi-asserted-by":"publisher","first-page":"3660","DOI":"10.1182\/blood-2010-05-284919","volume":"116","author":"P Chen","year":"2010","unstructured":"Chen P, Li C, Lang S, Zhu G, Reheman A, Spring CM, et al. Animal model of fetal and neonatal immune thrombocytopenia: role of neonatal Fc receptor in the pathogenesis and therapy. Blood. 2010;116(18):3660\u20138. https:\/\/doi.org\/10.1182\/blood-2010-05-284919.","journal-title":"Blood"},{"issue":"6504","key":"2279_CR23","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/372336a0","volume":"372","author":"WP Burmeister","year":"1994","unstructured":"Burmeister WP, Gastinel LN, Simister NE, Blum ML, Bjorkman PJ. Crystal structure at 2.2 \u00c5 resolution of the MHC-related neonatal Fc receptor. Nature. 1994;372(6504):336\u201343. https:\/\/doi.org\/10.1038\/372336a0.","journal-title":"Nature"},{"issue":"6203","key":"2279_CR24","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/337184a0","volume":"337","author":"NE Simister","year":"1989","unstructured":"Simister NE, Mostov KE. An fc receptor structurally related to MHC class I antigens. Nature. 1989;337(6203):184\u20137. https:\/\/doi.org\/10.1038\/337184a0.","journal-title":"Nature"},{"issue":"6","key":"2279_CR25","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1369\/0022155417705095","volume":"65","author":"S Latvala","year":"2017","unstructured":"Latvala S, Jacobsen B, Otteneder MB, Herrmann A, Kronenberg S. Distribution of FcRn across species and tissues. J Histochem Cytochem: Off J Histochem Soc. 2017;65(6):321\u201333. https:\/\/doi.org\/10.1369\/0022155417705095. PubMed PMID: 28402755; PubMedCentral PMCID: PMC5625855.","journal-title":"J Histochem Cytochem: Off J Histochem Soc"},{"issue":"6","key":"2279_CR26","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/s0143-4004(03)00041-9","volume":"24","author":"A Gafencu","year":"2003","unstructured":"Gafencu A, Heltianu C, Burlacu A, Hunziker W, Simionescu M. Investigation of IgG receptors expressed on the surface of human placental endothelial cells. Placenta. 2003;24(6):664\u201376. https:\/\/doi.org\/10.1016\/s0143-4004(03)00041-9.","journal-title":"Placenta"},{"issue":"7","key":"2279_CR27","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1172\/JCI6968","volume":"104","author":"BL Dickinson","year":"1999","unstructured":"Dickinson BL, Badizadegan K, Wu Z, Ahouse JC, Zhu X, Simister NE, et al. Bidirectional FcRn-dependent IgG transport in a polarized human intestinal epithelial cell line. J Clin Invest. 1999;104(7):903\u201311. https:\/\/doi.org\/10.1172\/JCI6968.","journal-title":"J Clin Invest"},{"issue":"15","key":"2279_CR28","doi-asserted-by":"publisher","first-page":"1371156","DOI":"10.3389\/fimmu.2024.1371156","volume":"16","author":"K Togami","year":"2024","unstructured":"Togami K, Wolf W, Olson LC, Card M, Shen L, Schaefer A, et al. Impact of mAb-FcRn affinity on IgG transcytosis across human well-differentiated airway epithelium. Front Immunol. 2024;16(15):1371156. https:\/\/doi.org\/10.3389\/fimmu.2024.1371156. PubMed PMID: 39351230; PubMedCentral PMCID: PMC11439726.","journal-title":"Front Immunol"},{"issue":"14","key":"2279_CR29","doi-asserted-by":"publisher","first-page":"E2862","DOI":"10.1073\/pnas.1618291114","volume":"114","author":"M Pyzik","year":"2017","unstructured":"Pyzik M, Rath T, Kuo TT, Win S, Baker K, Hubbard JJ, et al. Hepatic FcRn regulates albumin homeostasis and susceptibility to liver injury. Proc Natl Acad Sci U S A. 2017;114(14):E2862\u201371. https:\/\/doi.org\/10.1073\/pnas.1618291114. PubMed PMID: 28330995; PubMedCentral PMCID: PMC5389309.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"2279_CR30","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1681\/ASN.V114632","volume":"11","author":"JP Haymann","year":"2000","unstructured":"Haymann JP, Levraud JP, Bouet S, Kappes V, Hag\u00e8ge J, Nguyen G, et al. Characterization and localization of the neonatal fc receptor in adult human kidney. J Am Soc Nephrol. 2000;11(4):632. https:\/\/doi.org\/10.1681\/ASN.V114632.","journal-title":"J Am Soc Nephrol"},{"issue":"15","key":"2279_CR31","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.260912","volume":"136","author":"A Pannek","year":"2023","unstructured":"Pannek A, Becker-Gotot J, Dower SK, Verhagen AM, Gleeson PA. The endosomal system of primary human vascular endothelial cells and albumin\u2013FcRn trafficking. J Cell Sci. 2023;136(15):jcs260912. https:\/\/doi.org\/10.1242\/jcs.260912.","journal-title":"J Cell Sci"},{"issue":"5","key":"2279_CR32","doi-asserted-by":"publisher","first-page":"3266","DOI":"10.4049\/jimmunol.166.5.3266","volume":"166","author":"X Zhu","year":"2001","unstructured":"Zhu X, Meng G, Dickinson BL, Li X, Mizoguchi E, Miao L, et al. MHC class I-related neonatal Fc receptor for IgG is functionally expressed in monocytes, intestinal macrophages, and dendritic cells. J Immunol. 2001;166(5):3266\u201376. https:\/\/doi.org\/10.4049\/jimmunol.166.5.3266.","journal-title":"J Immunol"},{"issue":"7","key":"2279_CR33","doi-asserted-by":"publisher","first-page":"3528","DOI":"10.4049\/jimmunol.170.7.3528","volume":"170","author":"DC Roopenian","year":"2003","unstructured":"Roopenian DC, Christianson GJ, Sproule TJ, Brown AC, Akilesh S, Jung N, et al. The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs. J Immunol. 2003;170(7):3528\u201333. https:\/\/doi.org\/10.4049\/jimmunol.170.7.3528.","journal-title":"J Immunol"},{"issue":"3","key":"2279_CR34","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1084\/jem.20021829","volume":"197","author":"C Chaudhury","year":"2003","unstructured":"Chaudhury C, Mehnaz S, Robinson JM, Hayton WL, Pearl DK, Roopenian DC, et al. The major histocompatibility complex-related fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan. J Exp Med. 2003;197(3):315\u201322. https:\/\/doi.org\/10.1084\/jem.20021829. PubMed PMID: 12566415; PubMedCentral PMCID: PMC2193842.","journal-title":"J Exp Med"},{"issue":"9","key":"2279_CR35","doi-asserted-by":"publisher","first-page":"2819","DOI":"10.1002\/(SICI)1521-4141(199909)29:09<2819::AID-IMMU2819>3.0.CO;2-6","volume":"29","author":"JK Kim","year":"1999","unstructured":"Kim JK, Firan M, Radu CG, Kim CH, Ghetie V, Ward ES. Mapping the site on human IgG for binding of the MHC class I-related receptor. FcRn Eur J Immunol. 1999;29(9):2819\u201325. https:\/\/doi.org\/10.1002\/(SICI)1521-4141(199909)29:09%3c2819::AID-IMMU2819%3e3.0.CO;2-6.","journal-title":"FcRn Eur J Immunol"},{"issue":"1","key":"2279_CR36","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/ncomms1607","volume":"3","author":"JT Andersen","year":"2012","unstructured":"Andersen JT, Dalhus B, Cameron J, Daba MB, Plumridge A, Evans L, et al. Structure-based mutagenesis reveals the albumin-binding site of the neonatal fc receptor. Nat Commun. 2012;3(1):610. https:\/\/doi.org\/10.1038\/ncomms1607.","journal-title":"Nat Commun"},{"issue":"50","key":"2279_CR37","doi-asserted-by":"publisher","first-page":"34583","DOI":"10.1074\/jbc.M114.587675","volume":"289","author":"KMK Sand","year":"2014","unstructured":"Sand KMK, Bern M, Nilsen J, Dalhus B, Gunnarsen KS, Cameron J, et al. Interaction with both domain I and III of albumin is required for optimal pH-dependent binding to the neonatal fc receptor (FcRn)*. J Biol Chem. 2014;289(50):34583\u201394. https:\/\/doi.org\/10.1074\/jbc.M114.587675.","journal-title":"J Biol Chem"},{"key":"2279_CR38","doi-asserted-by":"publisher","unstructured":"Ghetie V, Hubbard JG, Kim JK, Tsen MF, Lee Y, Ward ES. Abnormally short serum half-lives of IgG in beta 2-microglobulin-deficient mice. Eur J Immunol. 1996 Mar;26(3). https:\/\/doi.org\/10.1002\/eji.1830260327. PubMed PMID: 8605939.","DOI":"10.1002\/eji.1830260327"},{"issue":"2","key":"2279_CR39","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1093\/intimm\/dxg018","volume":"15","author":"ES Ward","year":"2003","unstructured":"Ward ES, Zhou J, Ghetie V, Ober RJ. Evidence to support the cellular mechanism involved in serum IgG homeostasis in humans. Int Immunol. 2003;15(2):187\u201395. https:\/\/doi.org\/10.1093\/intimm\/dxg018.","journal-title":"Int Immunol"},{"issue":"4","key":"2279_CR40","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1083\/jcb.200809122","volume":"185","author":"S Tzaban","year":"2009","unstructured":"Tzaban S, Massol RH, Yen E, Hamman W, Frank SR, Lapierre LA, et al. The recycling and transcytotic pathways for IgG transport by FcRn are distinct and display an inherent polarity. J Cell Biol. 2009;185(4):673\u201384. https:\/\/doi.org\/10.1083\/jcb.200809122.","journal-title":"J Cell Biol"},{"issue":"4","key":"2279_CR41","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.4049\/jimmunol.172.4.2021","volume":"172","author":"RJ Ober","year":"2004","unstructured":"Ober RJ, Martinez C, Vaccaro C, Zhou J, Ward ES. Visualizing the site and dynamics of IgG salvage by the MHC class I-related receptor, FcRn. J Immunol (baltim Md,: 1950). 2004;172(4):2021\u20139. https:\/\/doi.org\/10.4049\/jimmunol.172.4.2021.","journal-title":"J Immunol (baltim Md,: 1950)"},{"issue":"30","key":"2279_CR42","doi-asserted-by":"publisher","first-page":"11076","DOI":"10.1073\/pnas.0402970101","volume":"101","author":"RJ Ober","year":"2004","unstructured":"Ober RJ, Martinez C, Lai X, Zhou J, Ward ES. Exocytosis of IgG as mediated by the receptor, FcRn: an analysis at the single-molecule level. Proc Natl Acad Sci. 2004;101(30):11076\u201381. https:\/\/doi.org\/10.1073\/pnas.0402970101.","journal-title":"Proc Natl Acad Sci"},{"issue":"2","key":"2279_CR43","doi-asserted-by":"publisher","first-page":"502","DOI":"10.4161\/mabs.27765","volume":"6","author":"N Chen","year":"2014","unstructured":"Chen N, Wang W, Fauty S, Fang Y, Hamuro L, Hussain A, et al. The effect of the neonatal Fc receptor on human IgG biodistribution in mice. MAbs. 2014;6(2):502\u20138. https:\/\/doi.org\/10.4161\/mabs.27765.","journal-title":"MAbs"},{"issue":"23","key":"2279_CR44","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2004325117","volume":"117","author":"S Borghi","year":"2020","unstructured":"Borghi S, Bournazos S, Thulin NK, Li C, Gajewski A, Sherwood RW, et al. FcRn, but not Fc\u03b3Rs, drives maternal-fetal transplacental transport of human IgG antibodies. Proc Natl Acad Sci U S A. 2020;117(23):12943. https:\/\/doi.org\/10.1073\/pnas.2004325117.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"2279_CR45","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/s0198-8859(00)00244-5","volume":"62","author":"F Antohe","year":"2001","unstructured":"Antohe F, R\u0103dulescu L, Gafencu A, Ghe\u0163ie V, Simionescu M. Expression of functionally active FcRn and the differentiated bidirectional transport of IgG in human placental endothelial cells. Hum Immunol. 2001;62(2):93\u2013105. https:\/\/doi.org\/10.1016\/s0198-8859(00)00244-5.","journal-title":"Hum Immunol"},{"issue":"10","key":"2279_CR46","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25105224","volume":"25","author":"A Di Ludovico","year":"2024","unstructured":"Di Ludovico A, Rinaldi M, Mainieri F, Di Michele S, Girlando V, Ciarelli F, et al. Molecular mechanisms of fetal and neonatal lupus: a narrative review of an autoimmune disease transferal across the placenta. Int J Mol Sci. 2024;25(10):5224. https:\/\/doi.org\/10.3390\/ijms25105224.","journal-title":"Int J Mol Sci"},{"key":"2279_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.112583","volume":"138","author":"S Qian","year":"2024","unstructured":"Qian S, Zhang D, Yang Z, Li R, Zhang X, Gao F, et al. The role of immunoglobulin transport receptor, neonatal fc receptor in mucosal infection and immunity and therapeutic intervention. Int Immunopharmacol. 2024;138:112583. https:\/\/doi.org\/10.1016\/j.intimp.2024.112583.","journal-title":"Int Immunopharmacol"},{"issue":"6","key":"2279_CR48","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens12060817","volume":"12","author":"Y Zhou","year":"2023","unstructured":"Zhou Y, Jiang S. Roles of FcRn in antigen-presenting cells during autoimmunity and a clinical evaluation of efgartigimod as an FcRn blocker. Pathogens. 2023;12(6):817. https:\/\/doi.org\/10.3390\/pathogens12060817.","journal-title":"Pathogens"},{"issue":"15","key":"2279_CR49","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1091\/mbc.E13-04-0174","volume":"24","author":"AW Weflen","year":"2013","unstructured":"Weflen AW, Baier N, Tang QJ, Van den Hof M, Blumberg RS, Lencer WI, et al. Multivalent immune complexes divert FcRn to lysosomes by exclusion from recycling sorting tubules. Mol Biol Cell. 2013;24(15):2398\u2013405. https:\/\/doi.org\/10.1091\/mbc.E13-04-0174.","journal-title":"Mol Biol Cell"},{"key":"2279_CR50","doi-asserted-by":"publisher","unstructured":"Ye L, Liu X, Rout SN, Li Z, Yan Y, Lu L, et al. The MHC class II-associated invariant chain interacts with the neonatal fc gamma receptor and modulates its trafficking to endosomal\/lysosomal compartments. J Immunol (baltim Md,: 1950). 2008;181(4):2572\u201385. https:\/\/doi.org\/10.4049\/jimmunol.181.4.2572. PubMed PMID: 18684948; PubMed Central PMCID: PMC2667114.","DOI":"10.4049\/jimmunol.181.4.2572"},{"issue":"6","key":"2279_CR51","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/j.immuni.2013.11.003","volume":"39","author":"K Baker","year":"2013","unstructured":"Baker K, Rath T, Flak MB, Arthur JC, Chen Z, Glickman JN, et al. Neonatal Fc receptor expression in dendritic cells mediates protective immunity against colorectal cancer. Immunity. 2013;39(6):1095\u2013107. https:\/\/doi.org\/10.1016\/j.immuni.2013.11.003.","journal-title":"Immunity"},{"issue":"4","key":"2279_CR52","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1046\/j.1365-2567.1996.d01-775.x","volume":"89","author":"EJ Israel","year":"1996","unstructured":"Israel EJ, Wilsker DF, Hayes KC, Schoenfeld D, Simister NE. Increased clearance of IgG in mice that lack \u03b22-microglobulin: possible protective role of FcRn. Immunology. 1996;89(4):573\u20138. https:\/\/doi.org\/10.1046\/j.1365-2567.1996.d01-775.x.","journal-title":"Immunology"},{"key":"2279_CR53","doi-asserted-by":"crossref","unstructured":"Christianson GJ, Brooks W, Vekasi S, Manolfi EA, Niles J, Roopenian SL, et al. Beta 2-microglobulin-deficient mice are protected from hypergammaglobulinemia and have defective antibody responses because of increased IgG catabolism. J Immunol (baltim Md,: 1950). 1997;159(10):4781\u201392. PubMed PMID: 9366402.","DOI":"10.4049\/jimmunol.159.10.4781"},{"issue":"4","key":"2279_CR54","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001011","volume":"8","author":"E Coutinho","year":"2021","unstructured":"Coutinho E, Jacobson L, Shock A, Smith B, Vernon A, Vincent A. Inhibition of maternal-to-fetal transfer of IgG antibodies by FcRn blockade in a mouse model of arthrogryposis multiplex congenita. Neurol Neuroimmunol Neuroinflammation. 2021;8(4):e1011. https:\/\/doi.org\/10.1212\/NXI.0000000000001011.","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"issue":"3","key":"2279_CR55","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s40259-025-00708-2","volume":"39","author":"TT Gj\u00f8lberg","year":"2025","unstructured":"Gj\u00f8lberg TT, Mester S, Calamera G, Telstad JS, Sandlie I, Andersen JT. Targeting the neonatal Fc receptor in autoimmune diseases: pipeline and progress. BioDrugs. 2025;39(3):373\u2013409. https:\/\/doi.org\/10.1007\/s40259-025-00708-2.","journal-title":"BioDrugs"},{"issue":"10","key":"2279_CR56","doi-asserted-by":"publisher","first-page":"4372","DOI":"10.1172\/JCI97911","volume":"128","author":"P Ulrichts","year":"2018","unstructured":"Ulrichts P, Guglietta A, Dreier T, van Bragt T, Hanssens V, Hofman E, et al. Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans. J Clin Invest. 2018;128(10):4372\u201386. https:\/\/doi.org\/10.1172\/JCI97911.","journal-title":"J Clin Invest"},{"issue":"Suppl 1","key":"2279_CR57","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.ard.2025.05.025","volume":"84","author":"H Chinoy","year":"2025","unstructured":"Chinoy H, Rodriguez-Garcia S, Neto A, Papadopoulou D, Baelen BV, Duncombe P, et al. OP0002 efficacy and safety of efgartigimod PH20 SC in adult participants with active idiopathic inflammatory myopathy: phase 2 results from the ALKIVIA study. Ann Rheum Dis. 2025;84(Suppl 1):2\u20133. https:\/\/doi.org\/10.1016\/j.ard.2025.05.025.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 1","key":"2279_CR58","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ard.2025.05.065","volume":"84","author":"I Peene","year":"2025","unstructured":"Peene I, Verstappen GM, Deprez J, Kroese FGM, Arends S, Kelly A, et al. OP0041\u2005treatment of primary Sj\u00f6gren\u2019s disease by blocking FcRn: clinical and translational data from RHO, a phase 2 randomized, placebo controlled, double-blind, proof-of-concept study with efgartigimod. Ann Rheum Dis. 2025;84(Suppl 1):37. https:\/\/doi.org\/10.1016\/j.ard.2025.05.065.","journal-title":"Ann Rheum Dis"},{"key":"2279_CR59","unstructured":"Argenx. A phase 2\/3, randomized, double-blinded, placebo-controlled, parallel-group, 2-arm, multicenter, operationally seamless study to evaluate the efficacy, safety, tolerability, pharmacodynamics, pharmacokinetics, and immunogenicity of efgartigimod PH20 SC in participants aged 18 years and older with active idiopathic inflammatory myopathy [Clinical trial registration] [Internet]. clinicaltrials.gov; 2025 Jul [cited 2025 Sep 26]. Clinical trial registration no.: NCT05523167. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05523167."},{"key":"2279_CR60","unstructured":"Argenx. A phase 3, single-arm, multicenter, open-label extension of study ARGX-113-2007 to investigate the long-term safety, tolerability, and efficacy of efgartigimod PH20 SC in participants aged 18 years and older with active idiopathic inflammatory myopathy [Clinical trial registration] [Internet]. clinicaltrials.gov; 2025 Aug [cited 2025 Sep 26]. Clinical trial registration no.: NCT05979441. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05979441."},{"key":"2279_CR61","unstructured":"Argenx. A phase 3 randomized, double-blinded, placebo-controlled multicenter trial with open-label extension to evaluate the efficacy, safety, and tolerability of efgartigimod PH20 subcutaneous administered by prefilled syringe in adult patients with primary sj\u00f6gren\u2019s disease [Clinical trial registration] [Internet]. clinicaltrials.gov; 2025 Sep [cited 2025 Sep 26]. Clinical trial registration no.: NCT06684847. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06684847."},{"key":"2279_CR62","unstructured":"Argenx. A multicenter, randomized, double-blinded, placebo-controlled, proof-of-concept study to evaluate the efficacy and safety of efgartigimod in chinese patients with lupus nephritis [Clinical trial registration] [Internet]. clinicaltrials.gov; 2025 Aug [cited 2025 Sep 26]. Clinical trial registration no.: NCT05810948. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05810948."},{"key":"2279_CR63","unstructured":"Argenx. A randomized, double-blinded, placebo-controlled, phase 2, parallel-group study to evaluate the efficacy, safety, tolerability, pharmacodynamics, pharmacokinetics, and immunogenicity of efgartigimod PH20 SC in adult participants with systemic sclerosis [Clinical trial registration] [Internet]. clinicaltrials.gov; 2025 Aug [cited 2025 Sep 26]. Clinical trial registration no.: NCT06655155. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06655155."},{"key":"2279_CR64","unstructured":"Baker MC. A phase IIa, single-site, open-label study of efgartigimod in patients with IgG4-related disease [Clinical trial registration] [Internet]. clinicaltrials.gov; 2025 Aug [cited 2025 Sep 26]. Clinical trial registration no.: NCT07025330. Available from: https:\/\/clinicaltrials.gov\/study\/NCT07025330."},{"issue":"1","key":"2279_CR65","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2025.2461191","volume":"17","author":"NP Seth","year":"2025","unstructured":"Seth NP, Xu R, DuPrie M, Choudhury A, Sihapong S, Tyler S, et al. Nipocalimab, an immunoselective FcRn blocker that lowers IgG and has unique molecular properties. MAbs. 2025;17(1):2461191. https:\/\/doi.org\/10.1080\/19420862.2025.2461191.","journal-title":"MAbs"},{"issue":"4","key":"2279_CR66","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1002\/cpt.1276","volume":"105","author":"LE Ling","year":"2019","unstructured":"Ling LE, Hillson JL, Tiessen RG, Bosje T, van Iersel MP, Nix DJ, et al. M281, an anti\u2010FcRn antibody: pharmacodynamics, pharmacokinetics, and safety across the full range of IgG reduction in a first\u2010in-human study. Clin Pharmacol Ther. 2019;105(4):1031\u20139. https:\/\/doi.org\/10.1002\/cpt.1276.","journal-title":"Clin Pharmacol Ther"},{"key":"2279_CR67","unstructured":"Janssen Research &amp; Development, LLC. A Randomized, Placebo-controlled, Double-blind, Multicenter Study to Assess the Efficacy and Safety of Nipocalimab in Adults With Primary Sjogren\u2019s Syndrome (pSS) [Clinical trial registration] [Internet]. clinicaltrials.gov; 2025 Nov [cited 2025 Nov 13]. Clinical trial registration no.: NCT04968912. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04968912."},{"issue":"Suppl 1","key":"2279_CR68","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1136\/annrheumdis-2024-eular.LBA90","volume":"83","author":"JE Gottenberg","year":"2024","unstructured":"Gottenberg JE, Sivils K, Campbell K, Idokogi J, Lo KH, Liva S, et al. LBA0010 efficacy and safety of Nipocalimab, an anti-FcRn monoclonal antibody, in primary Sjogren\u2019s disease: results from a phase 2, multicenter, randomized, placebo-controlled, double-blind study (DAHLIAS). Ann Rheum Dis. 2024;83(Suppl 1):240\u2013240. https:\/\/doi.org\/10.1136\/annrheumdis-2024-eular.LBA90.","journal-title":"Ann Rheum Dis"},{"key":"2279_CR69","unstructured":"Observed and simulated pharmacokinetics and pharmacodynamics of nipocalimab, a fully human FcRn blocking monoclonal antibody, in adults with Sj\u00f6gren\u2019s disease: results from a phase 2, multicenter, randomized, placebo-controlled, double-blind study. ACR Meeting Abstracts [Internet]. 2024 Nov 17 [cited 2025 Feb 23]. Available from: https:\/\/acrabstracts.org\/abstract\/observed-and-simulated-pharmacokinetics-and-pharmacodynamics-of-nipocalimab-a-fully-human-fcrn-blocking-monoclonal-antibody-in-adults-with-sjogrens-disease-results-from-a-phase-2-multicen\/."},{"key":"2279_CR70","unstructured":"Pharmacodynamic effects of nipocalimab on disease biomarkers in patients with moderate-to-severe active Sj\u00f6gren\u2019s disease: results from a multicenter, randomized, double-blinded, placebo-controlled phase 2 study. ACR Meeting Abstracts [Internet]. 2024 Nov 17 [cited 2025 Feb 23]. Available from: https:\/\/acrabstracts.org\/abstract\/pharmacodynamic-effects-of-nipocalimab-on-disease-biomarkers-in-patients-with-moderate-to-severe-active-sjogrens-disease-results-from-a-multicenter-randomized-double-blinded-placebo-controlled-p\/."},{"key":"2279_CR71","unstructured":"Janssen Research &amp; Development, LLC. A randomized, placebo-controlled, double-blind, multicenter phase 3 protocol to assess the efficacy and safety of nipocalimab in adults with moderate to severe sjogren\u2019s disease (SjD) [Clinical trial registration] [Internet]. clinicaltrials.gov; 2025 Sep [cited 2025 Sep 27]. Clinical trial registration no.: NCT06741969. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06741969."},{"issue":"2","key":"2279_CR72","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2024-004278","volume":"10","author":"PC Taylor","year":"2024","unstructured":"Taylor PC, Schett G, Huizinga TW, Wang Q, Ibrahim F, Zhou B, et al. Nipocalimab, an anti-FcRn monoclonal antibody, in participants with moderate to severe active rheumatoid arthritis and inadequate response or intolerance to anti-TNF therapy: results from the phase 2a IRIS-RA study. RMD Open. 2024;10(2):e004278. https:\/\/doi.org\/10.1136\/rmdopen-2024-004278. PubMed PMID: 38942592; PubMedCentral PMCID: PMC11227837.","journal-title":"RMD Open"},{"key":"2279_CR73","unstructured":"Janssen Research &amp; Development, LLC. A phase 2a multicenter, randomized, double blind, parallel, proof of concept study evaluating the efficacy and safety of nipocalimab and certolizumab combination therapy in participants with active rheumatoid arthritis despite prior treatment with advanced therapies (bDMARD or tsDMARD) [Clinical trial registration] [Internet]. clinicaltrials.gov; 2025 Apr [cited 2025 Sep 27]. Clinical trial registration no.: NCT06028438. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06028438."},{"key":"2279_CR74","unstructured":"Janssen Research &amp; Development, LLC. A phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of nipocalimab in participants with active idiopathic inflammatory myopathies [Clinical trial registration] [Internet]. clinicaltrials.gov; 2025 Sep [cited 2025 Sep 27]. Clinical trial registration no.: NCT05379634. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05379634."},{"key":"2279_CR75","unstructured":"Janssen Research &amp; Development, LLC. A multicenter, randomized, double-blind, placebo-controlled, parallel-group study of nipocalimab in adult participants with active systemic lupus erythematosus [Clinical trial registration] [Internet]. clinicaltrials.gov; 2025 Jul [cited 2025 Sep 30]. Clinical trial registration no.: NCT04882878. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04882878."},{"key":"2279_CR76","unstructured":"Janssen Research &amp; Development, LLC. A phase 2, multicenter, randomized, double-blind, placebo-controlled study of nipocalimab in adult participants with active lupus nephritis [Clinical trial registration] [Internet]. clinicaltrials.gov; 2025 Sep [cited 2025 Sep 30]. Clinical trial registration no.: NCT04883619. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04883619."},{"issue":"12","key":"2279_CR77","doi-asserted-by":"publisher","first-page":"3122","DOI":"10.1210\/clinem\/dgad381","volume":"108","author":"GJ Kahaly","year":"2023","unstructured":"Kahaly GJ, Dolman PJ, Wolf J, Giers BC, Elflein HM, Jain AP, et al. Proof-of-concept and randomized, placebo-controlled trials of an FcRn inhibitor, batoclimab, for thyroid eye disease. J Clin Endocrinol Metab. 2023;108(12):3122\u201334. https:\/\/doi.org\/10.1210\/clinem\/dgad381. PubMed PMID: 37390454; PubMedCentral PMCID: PMC10655547.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2279_CR78","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1007\/s40264-025-01549-2","volume":"48","author":"T Hardy","year":"2025","unstructured":"Hardy T, Liang S, Tedeschi P, Lin E, Brinton EA, Davidson MH. Impact of batoclimab treatment on LDL-C with and without coadministration of atorvastatin: results from a phase I randomized study in healthy participants. Drug Saf. 2025;48(9):993\u20131004. https:\/\/doi.org\/10.1007\/s40264-025-01549-2.","journal-title":"Drug Saf"},{"key":"2279_CR79","unstructured":"Macias WL, Liang S, Ahn H, Yong H, Jung M, Yoon M, et al. Anti-FcRn antibody or antigen binding fragment thereof with improved stability [Internet]. US11926669B2, 2024 [cited 2025 Sep 16]. Available from: https:\/\/patents.google.com\/patent\/US11926669B2\/en."},{"key":"2279_CR80","unstructured":"Immunovant, Inc. [Internet]. 2023 [cited 2025 Sep 16]. Immunovant announces positive initial IMVT-1402 phase 1 SAD and 300 mg subcutaneous MAD results. Available from: https:\/\/www.immunovant.com\/investors\/news-events\/press-releases\/detail\/51\/immunovant-announces-positive-initial-imvt-1402-phase-1-sad."},{"key":"2279_CR81","unstructured":"Immunovant Sciences GmbH. A phase 2b, multicenter, double-blind, placebo-controlled randomized withdrawal study to assess the efficacy, safety, and tolerability of IMVT-1402 in adult participants with active, difficult to treat, ACPA-positive rheumatoid arthritis [Clinical trial registration] [Internet]. clinicaltrials.gov; 2025 Sep [cited 2025 Sep 27]. Clinical trial registration no.: NCT06754462. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06754462."},{"key":"2279_CR82","unstructured":"Immunovant Sciences GmbH. A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Primary Sjogren\u2019s Disease With Moderate to Severe Systemic Disease Activity [Clinical trial registration] [Internet]. clinicaltrials.gov; 2025 Jul [cited 2025 Nov 15]. Clinical trial registration no.: NCT06979531. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06979531."},{"key":"2279_CR83","unstructured":"Immunovant Sciences GmbH. A phase 2b, randomized, double-blind, placebo-controlled study to assess the safety, tolerability, and efficacy of IMVT-1402 in participants with active subacute cutaneous lupus erythematosus (SCLE) and\/or chronic cutaneous lupus erythematosus (CCLE) with or without systemic manifestations [Clinical trial registration] [Internet]. clinicaltrials.gov; 2025 Sep [cited 2025 Sep 27]. Clinical trial registration no.: NCT06980805. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06980805."},{"issue":"6","key":"2279_CR84","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1172\/JCI78084","volume":"125","author":"J Suurmond","year":"2015","unstructured":"Suurmond J, Diamond B. Autoantibodies in systemic autoimmune diseases: specificity and pathogenicity. J Clin Invest. 2015;125(6):2194\u2013202. https:\/\/doi.org\/10.1172\/JCI78084. PubMed PMID:25938780; PubMedCentral PMCID:PMC4497746.","journal-title":"J Clin Invest"},{"issue":"10","key":"2279_CR85","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1136\/ard-2023-224692","volume":"82","author":"DS Pisetsky","year":"2023","unstructured":"Pisetsky DS. Annals of the rheumatic diseases collection on autoantibodies in the rheumatic diseases: new insights into pathogenesis and the development of novel biomarkers. Ann Rheum Dis. 2023;82(10):1243\u20137. https:\/\/doi.org\/10.1136\/ard-2023-224692. PubMed PMID: 37580110; PubMedCentral PMCID: PMC11149592.","journal-title":"Ann Rheum Dis"},{"key":"2279_CR86","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/429878","volume":"2015","author":"AB Paoliello-Paschoalato","year":"2015","unstructured":"Paoliello-Paschoalato AB, Marchi LF, de Andrade MF, Kabeya LM, Donadi EA, Lucisano-Valim YM. Fc\u03b3 and complement receptors and complement proteins in neutrophil activation in rheumatoid arthritis: contribution to pathogenesis and progression and modulation by natural products. Evid-based Complement Altern Med\u202f: Ecam. 2015;2015:429878. https:\/\/doi.org\/10.1155\/2015\/429878. PubMed PMID: 26346244; PubMedCentral PMCID: PMC4540990.","journal-title":"Evid-based Complement Altern Med : Ecam"},{"issue":"9","key":"2279_CR87","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/S1471-4906(01)02014-2","volume":"22","author":"HM Dijstelbloem","year":"2001","unstructured":"Dijstelbloem HM, Kallenberg CGM, van de Winkel JGJ. Inflammation in autoimmunity: receptors for IgG revisited. Trends Immunol. 2001;22(9):510\u20136. https:\/\/doi.org\/10.1016\/S1471-4906(01)02014-2.","journal-title":"Trends Immunol"},{"key":"2279_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2019.101339","volume":"45","author":"DJ Dijkstra","year":"2019","unstructured":"Dijkstra DJ, Joeloemsingh JV, Bajema IM, Trouw LA. Complement activation and regulation in rheumatic disease. Semin Immunol. 2019;45:101339. https:\/\/doi.org\/10.1016\/j.smim.2019.101339.","journal-title":"Semin Immunol"},{"issue":"3","key":"2279_CR89","doi-asserted-by":"publisher","first-page":"R64","DOI":"10.1186\/ar1926","volume":"8","author":"L Mathsson","year":"2006","unstructured":"Mathsson L, Lampa J, Mullazehi M, R\u00f6nnelid J. Immune complexes from rheumatoid arthritis synovial fluid induce Fc\u03b3RIIa dependent and rheumatoid factor correlated production of tumour necrosis factor-\u03b1 by peripheral blood mononuclear cells. Arthritis Res Ther. 2006;8(3):R64. https:\/\/doi.org\/10.1186\/ar1926. PubMed PMID: 16569263; PubMedCentral PMCID: PMC1526644.","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"2279_CR90","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/ncprheum0895","volume":"4","author":"K Elkon","year":"2008","unstructured":"Elkon K, Casali P. Nature and functions of autoantibodies. Nat Clin Pract Rheumatol. 2008;4(9):491\u20138. https:\/\/doi.org\/10.1038\/ncprheum0895. PubMed PMID: 18756274; PubMedCentral PMCID: PMC2703183.","journal-title":"Nat Clin Pract Rheumatol"},{"key":"2279_CR91","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3389\/fimmu.2022.924766","volume":"13","author":"W Qiu","year":"2022","unstructured":"Qiu W, Yu T, Deng GM. The role of organ-deposited IgG in the pathogenesis of multi-organ and tissue damage in systemic lupus erythematosus. Front Immunol. 2022;13:13. https:\/\/doi.org\/10.3389\/fimmu.2022.924766.","journal-title":"Front Immunol"},{"key":"2279_CR92","doi-asserted-by":"publisher","DOI":"10.37349\/ei.2025.1003208","volume":"5","author":"V Kasiraja","year":"2025","unstructured":"Kasiraja V, Bakar NAA, Suliman NA. Rheumatoid arthritis unmasked: the immune complex as a key driver of disease progression. Explor Immunol. 2025;5:1003208. https:\/\/doi.org\/10.37349\/ei.2025.1003208.","journal-title":"Explor Immunol"},{"issue":"20","key":"2279_CR93","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1161\/CIRCULATIONAHA.108.771170","volume":"120","author":"TN Mayadas","year":"2009","unstructured":"Mayadas TN, Tsokos GC, Tsuboi N. Mechanisms of immune complex\u2013mediated neutrophil recruitment and tissue injury. Circulation. 2009;120(20):2012\u201324. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.108.771170.","journal-title":"Circulation"},{"issue":"3","key":"2279_CR94","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1084\/jem.20020400","volume":"196","author":"GM Spiekermann","year":"2002","unstructured":"Spiekermann GM, Finn PW, Ward ES, Dumont J, Dickinson BL, Blumberg RS, et al. Receptor-mediated immunoglobulin G transport across mucosal barriers in adult life. J Exp Med. 2002;196(3):303\u201310. https:\/\/doi.org\/10.1084\/jem.20020400.","journal-title":"J Exp Med"},{"issue":"16","key":"2279_CR95","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/NEJMra2312718","volume":"392","author":"JB Bussel","year":"2025","unstructured":"Bussel JB, Cines DB, Blumberg RS. Neonatal Fc receptor \u2014 biology and therapeutics. N Engl J Med. 2025;392(16):1621\u201335. https:\/\/doi.org\/10.1056\/NEJMra2312718.","journal-title":"N Engl J Med"},{"issue":"2","key":"2279_CR96","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/uog.24891","volume":"60","author":"KJ Moise","year":"2022","unstructured":"Moise KJ, Oepkes D, Lopriore E, Bredius RGM. Targeting neonatal Fc receptor: potential clinical applications in pregnancy. Ultrasound Obstet Gynecol. 2022;60(2):167\u201375. https:\/\/doi.org\/10.1002\/uog.24891.","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"9","key":"2279_CR97","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1172\/JCI18838","volume":"113","author":"S Akilesh","year":"2004","unstructured":"Akilesh S, Petkova S, Sproule TJ, Shaffer DJ, Christianson GJ, Roopenian D. The MHC class I\u2013like Fc receptor promotes humorally mediated autoimmune disease. J Clin Invest. 2004;113(9):1328\u201333. https:\/\/doi.org\/10.1172\/JCI18838.","journal-title":"J Clin Invest"},{"key":"2279_CR98","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.bbi.2025.01.015","volume":"125","author":"NT Fiore","year":"2025","unstructured":"Fiore NT, Willcox KF, Dayani D, Zuberi YA, Heijnen CJ, Grace PM. Reducing IgG accumulation via neonatal Fc receptor (FcRn) blockade relieves neuropathic pain. Brain Behav Immun. 2025;125:371\u201387. https:\/\/doi.org\/10.1016\/j.bbi.2025.01.015.","journal-title":"Brain Behav Immun"},{"issue":"12","key":"2279_CR99","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0230401","volume":"15","author":"JF Dylewski","year":"2020","unstructured":"Dylewski JF, Tonsawan P, Garcia G, Lewis L, Blaine J. Podocyte-specific knockout of the neonatal Fc receptor (FcRn) results in differential protection depending on the model of glomerulonephritis. PLoS ONE. 2020;15(12):e0230401. https:\/\/doi.org\/10.1371\/journal.pone.0230401.","journal-title":"PLoS ONE"},{"key":"2279_CR100","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.intimp.2018.11.040","volume":"66","author":"B Smith","year":"2019","unstructured":"Smith B, Christodoulou L, Clargo A, Eddleston A, Greenslade K, Lightwood D, et al. Generation of two high affinity anti-mouse FcRn antibodies: inhibition of IgG recycling in wild type mice and effect in a mouse model of immune thrombocytopenia. Int Immunopharmacol. 2019;66:362\u20135. https:\/\/doi.org\/10.1016\/j.intimp.2018.11.040.","journal-title":"Int Immunopharmacol"},{"issue":"2","key":"2279_CR101","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.4049\/jimmunol.1003780","volume":"187","author":"DA Patel","year":"2011","unstructured":"Patel DA, Puig-Canto A, Challa DK, Perez Montoyo H, Ober RJ, Ward ES. Neonatal Fc receptor blockade by Fc engineering ameliorates arthritis in a murine model. J Immunol. 2011;187(2):1015\u201322. https:\/\/doi.org\/10.4049\/jimmunol.1003780.","journal-title":"J Immunol"},{"issue":"5","key":"2279_CR102","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1681\/ASN.2013050498","volume":"25","author":"F Olaru","year":"2014","unstructured":"Olaru F, Luo W, Suleiman H, St John PL, Ge L, Mezo AR, et al. Neonatal Fc receptor promotes immune complex-mediated glomerular disease. J Am Soc Nephrol. 2014;25(5):918\u201325. https:\/\/doi.org\/10.1681\/ASN.2013050498.","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"2279_CR103","doi-asserted-by":"publisher","first-page":"655","DOI":"10.4161\/mabs.25439","volume":"5","author":"DK Challa","year":"2013","unstructured":"Challa DK, Bussmeyer U, Khan T, Montoyo HP, Bansal P, Ober RJ, et al. Autoantibody depletion ameliorates disease in murine experimental autoimmune encephalomyelitis. MAbs. 2013;5(5):655\u20139. https:\/\/doi.org\/10.4161\/mabs.25439.","journal-title":"MAbs"},{"key":"2279_CR104","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00176","volume":"6","author":"AE Nixon","year":"2015","unstructured":"Nixon AE, Chen J, Sexton DJ, Muruganandam A, Bitonti AJ, Dumont J, et al. Fully human monoclonal antibody inhibitors of the neonatal Fc receptor reduce circulating IgG in non-human primates. Front Immunol. 2015;6:176. https:\/\/doi.org\/10.3389\/fimmu.2015.00176.","journal-title":"Front Immunol"},{"issue":"1","key":"2279_CR105","doi-asserted-by":"publisher","DOI":"10.1080\/1547691X.2025.2459934","volume":"22","author":"O Binazon","year":"2025","unstructured":"Binazon O, Cocco M, Thwaites D, Cooper C, Moshir M, Vanhoenacker P, et al. Effects of Efgartigimod treatment on humoral and cellular immune responses: analysis of T-cell-dependent antibody response in cynomolgus monkeys. J Immunotoxicol. 2025;22(1):2459934. https:\/\/doi.org\/10.1080\/1547691X.2025.2459934.","journal-title":"J Immunotoxicol"},{"issue":"8","key":"2279_CR106","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1080\/08916934.2022.2104261","volume":"55","author":"JT Guptill","year":"2022","unstructured":"Guptill JT, Sleasman JW, Steeland S, Sips M, Gelinas D, de Haard H, et al. Effect of FcRn antagonism on protective antibodies and to vaccines in IgG-mediated autoimmune diseases Pemphigus and generalised Myasthenia gravis. Autoimmunity. 2022;55(8):620\u201331. https:\/\/doi.org\/10.1080\/08916934.2022.2104261.","journal-title":"Autoimmunity"},{"key":"2279_CR107","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2021.100122","volume":"4","author":"J Lamamy","year":"2021","unstructured":"Lamamy J, Boulard P, Brachet G, Tourlet S, Gouilleux-Gruart V, Ramdani Y. \u201cWays in which the neonatal Fc-receptor is involved in autoimmunity.\u201d J Translational Autoimmunity. 2021;4:100122. https:\/\/doi.org\/10.1016\/j.jtauto.2021.100122.","journal-title":"J Translational Autoimmunity"},{"issue":"2","key":"2279_CR108","doi-asserted-by":"publisher","DOI":"10.1186\/ar4206","volume":"15","author":"RR Singh","year":"2013","unstructured":"Singh RR, Yang JQ, Kim PJ, Halder RC. Germline deletion of \u03b22 microglobulin or CD1d reduces anti-phospholipid antibody, but increases autoantibodies against non-phospholipid antigens in the NZB\/W F1 model of Lupus. Arthritis Res Ther. 2013;15(2):R47. https:\/\/doi.org\/10.1186\/ar4206.","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"2279_CR109","doi-asserted-by":"publisher","first-page":"2985","DOI":"10.4049\/jimmunol.167.5.2985","volume":"167","author":"OT Chan","year":"2001","unstructured":"Chan OT, Paliwal V, McNiff JM, Park SH, Bendelac A, Shlomchik MJ. Deficiency in beta(2)-microglobulin, but not CD1, accelerates spontaneous Lupus skin disease while inhibiting nephritis in MRL-fas(lpr) nice: an example of disease regulation at the organ level. J Immunol (baltim Md,: 1950). 2001;167(5):2985\u201390. https:\/\/doi.org\/10.4049\/jimmunol.167.5.2985.","journal-title":"J Immunol (baltim Md,: 1950)"},{"issue":"1","key":"2279_CR110","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.47","volume":"2","author":"P Brito-Zer\u00f3n","year":"2016","unstructured":"Brito-Zer\u00f3n P, Baldini C, Bootsma H, Bowman SJ, Jonsson R, Mariette X, et al. Sj\u00f6gren syndrome. Nat Rev Dis Primers. 2016;2(1):1. https:\/\/doi.org\/10.1038\/nrdp.2016.47.","journal-title":"Nat Rev Dis Primers"},{"issue":"7","key":"2279_CR111","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70297","volume":"6","author":"Y Hu","year":"2025","unstructured":"Hu Y, Wen B, Zhang Y, Wang X, Duan X, Li H, et al. Sj\u00f6gren\u2019s syndrome: epidemiology, classification criteria, molecular pathogenesis, diagnosis, and treatment. Medcomm. 2025;6(7):e70297. https:\/\/doi.org\/10.1002\/mco2.70297.","journal-title":"Medcomm"},{"issue":"5","key":"2279_CR112","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1093\/rheumatology\/kez142","volume":"60","author":"RI Fox","year":"2021","unstructured":"Fox RI, Fox CM, Gottenberg JE, D\u00f6rner T. Treatment of Sj\u00f6gren\u2019s syndrome: current therapy and future directions. Rheumatol (oxf Engl). 2021;60(5):2066\u201374. https:\/\/doi.org\/10.1093\/rheumatology\/kez142.","journal-title":"Rheumatol (oxf Engl)"},{"issue":"12","key":"2279_CR113","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.55563\/clinexprheumatol\/43z8gu","volume":"40","author":"V Manfr\u00e8","year":"2022","unstructured":"Manfr\u00e8 V, Chatzis LG, Cafaro G, Fonzetti S, Calvacchi S, Fulvio G, et al. Sj\u00f6gren\u2019s syndrome: one year in review 2022. Clin Exp Rheumatol. 2022;40(12):2211\u201324. https:\/\/doi.org\/10.55563\/clinexprheumatol\/43z8gu.","journal-title":"Clin Exp Rheumatol"},{"key":"2279_CR114","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/j.ard.2025.06.200","volume":"84","author":"I Peene","year":"2025","unstructured":"Peene I, Mariette X, Elewaut D, D\u00f6rner T, Bootsma H, Baker M, et al. Pos0844\u2005efficacy and safety of Efgartigimod ph20 subcutaneous by prefilled syringe in adults with primary Sj\u00f6gren\u2019s disease: a phase 3, randomized, double-blind, placebo-controlled, multicenter trial with open-label extension (Unity). Ann Rheum Dis. 2025;84:988\u20139. https:\/\/doi.org\/10.1016\/j.ard.2025.06.200.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"2279_CR115","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1172\/JCI3234","volume":"102","author":"DI Stott","year":"1998","unstructured":"Stott DI, Hiepe F, Hummel M, Steinhauser G, Berek C. Antigen-driven clonal proliferation of B cells within the target tissue of an autoimmune disease. The salivary glands of patients with Sj\u00f6gren\u2019s syndrome. J Clin Invest. 1998;102(5):938\u201346. https:\/\/doi.org\/10.1172\/JCI3234.","journal-title":"J Clin Invest"},{"issue":"1","key":"2279_CR116","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2478\/rir-2022-0001","volume":"3","author":"F Halilu","year":"2022","unstructured":"Halilu F, Christopher-Stine L. Myositis-specific antibodies: Overview and clinical utilization. Rheumatol Immunol Res. 2022;3(1):1\u201310. https:\/\/doi.org\/10.2478\/rir-2022-0001.","journal-title":"Rheumatol Immunol Res"},{"issue":"5","key":"2279_CR117","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1093\/rheumatology\/keac115","volume":"61","author":"AGS Oldroyd","year":"2022","unstructured":"Oldroyd AGS, Lilleker JB, Amin T, Aragon O, Bechman K, Cuthbert V, et al. British Society for Rheumatology guideline on management of paediatric, adolescent and adult patients with idiopathic inflammatory myopathy. Rheumatology Oxford. 2022;61(5):1760\u20138. https:\/\/doi.org\/10.1093\/rheumatology\/keac115.","journal-title":"Rheumatology Oxford"},{"key":"2279_CR118","doi-asserted-by":"publisher","first-page":"151","DOI":"10.2147\/ITT.S381472","volume":"13","author":"L Cassard","year":"2024","unstructured":"Cassard L, Seraly N, Riegert M, Patel A, Fernandez AP. Dermatomyositis: Practical guidance and unmet needs. ImmunoTargets Ther. 2024;13:151\u201372. https:\/\/doi.org\/10.2147\/ITT.S381472.","journal-title":"ImmunoTargets Ther"},{"issue":"12","key":"2279_CR119","doi-asserted-by":"publisher","first-page":"4006","DOI":"10.1093\/rheumatology\/kead298","volume":"62","author":"S Julien","year":"2023","unstructured":"Julien S, Van Der Woning B, De Ceuninck L, Briand E, Jaworski T, Roussel G, et al. Efgartigimod restores muscle function in a humanized mouse model of immune-mediated necrotizing myopathy. Rheumatology Oxford. 2023;62(12):4006\u201311. https:\/\/doi.org\/10.1093\/rheumatology\/kead298.","journal-title":"Rheumatology Oxford"},{"key":"2279_CR120","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2024-eular.3020","volume":"83","author":"CE Najem","year":"2024","unstructured":"Najem CE, Craig J, Christopher Stine L, Zazzetti F, Shu C, Noel W, et al. Ab0250 a phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trial of Nipocalimab in participants with active idiopathic inflammatory myopathies (spirea): study design. Ann Rheum Dis. 2024;83:1365. https:\/\/doi.org\/10.1136\/annrheumdis-2024-eular.3020.","journal-title":"Ann Rheum Dis"},{"key":"2279_CR121","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1447182","volume":"15","author":"M Yang","year":"2024","unstructured":"Yang M, Yuan J, Wang Y, Hao H, Zhang W, Wang Z, et al. Treatment of refractory immune-mediated necrotizing myopathy with Efgartigimod. Front Immunol. 2024;15:1447182. https:\/\/doi.org\/10.3389\/fimmu.2024.1447182.","journal-title":"Front Immunol"},{"key":"2279_CR122","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1495415","volume":"15","author":"Q Zeng","year":"2024","unstructured":"Zeng Q, Chen K, Zeng L, Xu L, Tan S. Case report: Rapid clinical improvement of anti-HMGCR immune-mediated necrotizing myopathy treated with Efgartigimod. Front Immunol. 2024;15:1495415. https:\/\/doi.org\/10.3389\/fimmu.2024.1495415.","journal-title":"Front Immunol"},{"issue":"1","key":"2279_CR123","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1136\/annrheumdis-2018-213518","volume":"78","author":"C Bergua","year":"2019","unstructured":"Bergua C, Chiavelli H, Allenbach Y, Arouche-Delaperche L, Arnoult C, Bourdenet G, et al. In vivo pathogenicity of IgG from patients with anti-SRP or anti-HMGCR autoantibodies in immune-mediated necrotising myopathy. Ann Rheum Dis. 2019;78(1):131\u20139. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213518.","journal-title":"Ann Rheum Dis"},{"issue":"10416","key":"2279_CR124","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1016\/S0140-6736(23)01525-8","volume":"402","author":"AD Matteo","year":"2023","unstructured":"Matteo AD, Bathon JM, Emery P. Rheumatoid arthritis. Lancet. 2023;402(10416):2019\u201333. https:\/\/doi.org\/10.1016\/S0140-6736(23)01525-8.","journal-title":"Lancet"},{"issue":"2","key":"2279_CR125","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1007\/s12016-021-08890-1","volume":"63","author":"MV Sokolova","year":"2022","unstructured":"Sokolova MV, Schett G, Steffen U. Autoantibodies in rheumatoid arthritis: Historical background and novel findings. Clin Rev Allergy Immunol. 2022;63(2):138\u201351. https:\/\/doi.org\/10.1007\/s12016-021-08890-1.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"2","key":"2279_CR126","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.immuni.2017.02.006","volume":"46","author":"G Firestein","year":"2017","unstructured":"Firestein G, McInnes IB. Immunopathogenesis of rheumatoid arthritis. Immunity. 2017;46(2):183\u201396. https:\/\/doi.org\/10.1016\/j.immuni.2017.02.006.","journal-title":"Immunity"},{"issue":"23","key":"2279_CR127","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.3472.3472","volume":"126","author":"LE Ling","year":"2015","unstructured":"Ling LE, Roy S, Daly T, Cochran E, Tyler S, Markowitz L, et al. M281: a therapeutic anti-FcRn blocking antibody for rapid clearance of IgG and IgG autoantibodies in immune cytopenias and other auto\/allo-immune disease. Blood. 2015;126(23):3472. https:\/\/doi.org\/10.1182\/blood.V126.23.3472.3472.","journal-title":"Blood"},{"key":"2279_CR128","unstructured":"Jnj.com [Internet]. 2025 [cited 2025 Sep 27]. Phase 2a DAISY proof-of-concept combination study update. Available from: https:\/\/www.jnj.com\/media-center\/press-releases\/phase-2a-daisy-proof-of-concept-combination-study-update."},{"issue":"9","key":"2279_CR129","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1136\/annrheumdis-2017-212627","volume":"77","author":"A Sohrabian","year":"2018","unstructured":"Sohrabian A, Mathsson-Alm L, Hansson M, Knight A, Lysholm J, Cornillet M, et al. Number of individual ACPA reactivities in synovial fluid immune complexes, but not serum anti-CCP2 levels, associate with inflammation and joint destruction in rheumatoid arthritis. Ann Rheum Dis. 2018;77(9):1345\u201353. https:\/\/doi.org\/10.1136\/annrheumdis-2017-212627.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"2279_CR130","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1136\/annrheumdis-2012-202861","volume":"73","author":"ME Doorenspleet","year":"2014","unstructured":"Doorenspleet ME, Klarenbeek PL, de Hair MJH, van Schaik BDC, Esveldt REE, van Kampen AHC, et al. Rheumatoid arthritis synovial tissue harbours dominant B-cell and plasma-cell clones associated with autoreactivity. Ann Rheum Dis. 2014;73(4):756\u201362. https:\/\/doi.org\/10.1136\/annrheumdis-2012-202861.","journal-title":"Ann Rheum Dis"},{"issue":"7987","key":"2279_CR131","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/s41586-023-06708-y","volume":"623","author":"F Zhang","year":"2023","unstructured":"Zhang F, Jonsson AH, Nathan A, Millard N, Curtis M, Xiao Q, et al. Deconstruction of rheumatoid arthritis synovium defines inflammatory subtypes. Nature. 2023;623(7987):616\u201324. https:\/\/doi.org\/10.1038\/s41586-023-06708-y.","journal-title":"Nature"},{"issue":"6","key":"2279_CR132","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1038\/s41591-022-01789-0","volume":"28","author":"F Rivellese","year":"2022","unstructured":"Rivellese F, Surace AEA, Goldmann K, Sciacca E, \u00c7ubuk C, Giorli G, et al. Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial. Nat Med. 2022;28(6):1256\u201368. https:\/\/doi.org\/10.1038\/s41591-022-01789-0.","journal-title":"Nat Med"},{"issue":"10","key":"2279_CR133","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.30330","volume":"14","author":"MA Ameer","year":"2022","unstructured":"Ameer MA, Chaudhry H, Mushtaq J, Khan OS, Babar M, Hashim T, et al. An overview of systemic Lupus erythematosus (SLE) pathogenesis, classification, and management. Cureus. 2022;14(10):e30330. https:\/\/doi.org\/10.7759\/cureus.30330.","journal-title":"Cureus"},{"issue":"2","key":"2279_CR134","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.semarthrit.2004.07.002","volume":"34","author":"Y Sherer","year":"2004","unstructured":"Sherer Y, Gorstein A, Fritzler MJ, Shoenfeld Y. Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients. Semin Arthritis Rheum. 2004;34(2):501\u201337. https:\/\/doi.org\/10.1016\/j.semarthrit.2004.07.002.","journal-title":"Semin Arthritis Rheum"},{"issue":"10","key":"2279_CR135","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/s41584-020-0480-7","volume":"16","author":"DS Pisetsky","year":"2020","unstructured":"Pisetsky DS, Lipsky PE. New insights into the role of antinuclear antibodies in systemic lupus erythematosus. Nat Rev Rheumatol. 2020;16(10):565\u201379. https:\/\/doi.org\/10.1038\/s41584-020-0480-7.","journal-title":"Nat Rev Rheumatol"},{"key":"2279_CR136","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2020.607515","volume":"8","author":"S De Carolis","year":"2020","unstructured":"De Carolis S, Garufi C, Garufi E, De Carolis MP, Botta A, Tabacco S, et al. Autoimmune congenital heart block: a review of biomarkers and management of pregnancy. Front Pediatr. 2020;8:607515. https:\/\/doi.org\/10.3389\/fped.2020.607515.","journal-title":"Front Pediatr"},{"key":"2279_CR137","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00199","volume":"10","author":"PL Meroni","year":"2019","unstructured":"Meroni PL, Tsokos GC. Editorial: systemic lupus erythematosus and antiphospholipid syndrome. Front Immunol. 2019;10:199. https:\/\/doi.org\/10.3389\/fimmu.2019.00199.","journal-title":"Front Immunol"},{"key":"2279_CR138","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/139365","volume":"2012","author":"S Yung","year":"2012","unstructured":"Yung S, Chan TM. Autoantibodies and resident renal cells in the pathogenesis of lupus nephritis: getting to know the unknown. Clin Dev Immunol. 2012;2012:139365. https:\/\/doi.org\/10.1155\/2012\/139365.","journal-title":"Clin Dev Immunol"},{"issue":"3","key":"2279_CR139","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s40744-023-00532-6","volume":"10","author":"SP Huang","year":"2023","unstructured":"Huang SP, Guisinger A, Averell C, Bell CF, Rubin B. Clinical and economic burden of systemic lupus erythematosus in the years preceding end-stage kidney disease diagnosis: A retrospective observational study. Rheumatol Ther. 2023;10(3):551\u201362. https:\/\/doi.org\/10.1007\/s40744-023-00532-6.","journal-title":"Rheumatol Ther"},{"issue":"Suppl 1","key":"2279_CR140","doi-asserted-by":"publisher","first-page":"152","DOI":"10.3899\/jrheum.2025-0390.PV127","volume":"52","author":"W Machua","year":"2025","unstructured":"Machua W, Manocha A, Sims J, Kaul M, Hunter J, Stallings N, et al. A survey of patients with SLE suggests limited knowledge of nephritis unless there is already chronic kidney disease. J Rheumatol. 2025;52(Suppl 1):152\u2013152. https:\/\/doi.org\/10.3899\/jrheum.2025-0390.PV127.","journal-title":"J Rheumatol"},{"issue":"4","key":"2279_CR141","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/art.42375","volume":"75","author":"M Hocaoglu","year":"2023","unstructured":"Hocaoglu M, Valenzuela-Almada MO, Dabit JY, Osei-Onomah SA, Chevet B, Giblon RE, et al. Incidence, prevalence, and mortality of lupus nephritis: a population-based study over four decades\u2014the lupus midwest network (LUMEN). Arthritis Rheumatol (hob NJ). 2023;75(4):567\u201373. https:\/\/doi.org\/10.1002\/art.42375. PubMed PMID: 36227575; PubMedCentral PMCID: PMC10065880.","journal-title":"Arthritis Rheumatol (hob NJ)"},{"issue":"6","key":"2279_CR142","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1186\/ar3528","volume":"13","author":"TK Nowling","year":"2011","unstructured":"Nowling TK, Gilkeson GS. Mechanisms of tissue injury in lupus nephritis. Arthritis Res Ther. 2011;13(6):250. https:\/\/doi.org\/10.1186\/ar3528.","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"2279_CR143","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.15444","volume":"27","author":"H Jeong","year":"2024","unstructured":"Jeong H, Choi S, Kang J, Lee JS, Choi Y, Park D, et al. Coexisting tubulointerstitial inflammation and damage is a risk factor for chronic kidney disease in patients with lupus nephritis. Int J Rheum Dis. 2024;27(12):e15444. https:\/\/doi.org\/10.1111\/1756-185X.15444.","journal-title":"Int J Rheum Dis"},{"issue":"4","key":"2279_CR144","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1002\/art.39499","volume":"68","author":"K Ichinose","year":"2016","unstructured":"Ichinose K, Ushigusa T, Nishino A, Nakashima Y, Suzuki T, Horai Y, et al. Lupus nephritis IgG induction of calcium\/calmodulin-dependent protein kinase IV expression in podocytes and alteration of their function. Arthritis Rheumatol. 2016;68(4):944\u201352. https:\/\/doi.org\/10.1002\/art.39499.","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"2279_CR145","doi-asserted-by":"publisher","first-page":"3445","DOI":"10.1172\/JCI99507","volume":"128","author":"K Maeda","year":"2018","unstructured":"Maeda K, Otomo K, Yoshida N, Abu-Asab MS, Ichinose K, Nishino T, et al. CaMK4 compromises podocyte function in autoimmune and nonautoimmune kidney disease. J Clin Invest. 2018;128(8):3445\u201359. https:\/\/doi.org\/10.1172\/JCI99507.","journal-title":"J Clin Invest"},{"key":"2279_CR146","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02113","volume":"9","author":"AP Ferretti","year":"2018","unstructured":"Ferretti AP, Bhargava R, Dahan S, Tsokos MG, Tsokos GC. Calcium\/calmodulin kinase IV controls the function of both T cells and kidney resident cells. Front Immunol. 2018;9:2113. https:\/\/doi.org\/10.3389\/fimmu.2018.02113.","journal-title":"Front Immunol"},{"issue":"9","key":"2279_CR147","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.147789","volume":"6","author":"R Bhargava","year":"2021","unstructured":"Bhargava R, Lehoux S, Maeda K, Tsokos MG, Krishfield S, Ellezian L, et al. Aberrantly glycosylated IgG elicits pathogenic signaling in podocytes and signifies Lupus nephritis. JCI insight. 2021;6(9):e147789. https:\/\/doi.org\/10.1172\/jci.insight.147789.","journal-title":"JCI insight"},{"issue":"5","key":"2279_CR148","doi-asserted-by":"publisher","first-page":"C1048","DOI":"10.1152\/ajpcell.00235.2019","volume":"317","author":"P Tonsawan","year":"2019","unstructured":"Tonsawan P, Dylewski J, Lewis L, Blaine J. Knockout of the neonatal Fc receptor in cultured podocytes alters IL-6 signaling and the actin cytoskeleton. Am J Physiol Cell Physiol. 2019;317(5):C1048\u201360. https:\/\/doi.org\/10.1152\/ajpcell.00235.2019.","journal-title":"Am J Physiol Cell Physiol"},{"issue":"4","key":"2279_CR149","doi-asserted-by":"publisher","DOI":"10.1016\/j.bdcasr.2024.100052","volume":"2","author":"K Nagatani","year":"2024","unstructured":"Nagatani K, Hayashi M. Long-term use of efgartigimod alfa in treating a young adult with childhood-onset systemic lupus erythematosus and generalized myasthenia gravis. Brain Dev Case Rep. 2024;2(4):100052. https:\/\/doi.org\/10.1016\/j.bdcasr.2024.100052.","journal-title":"Brain Dev Case Rep"},{"key":"2279_CR150","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1070","volume":"369","author":"RW Hunter","year":"2020","unstructured":"Hunter RW, Welsh N, Farrah TE, Gallacher PJ, Dhaun N. ANCA associated vasculitis. BMJ. 2020;369:m1070. https:\/\/doi.org\/10.1136\/bmj.m1070.","journal-title":"BMJ"},{"issue":"4","key":"2279_CR151","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1159\/000442323","volume":"1","author":"H Xiao","year":"2016","unstructured":"Xiao H, Hu P, Falk RJ, Jennette JC. Overview of the pathogenesis of ANCA-associated vasculitis. Kidney Dis. 2016;1(4):205\u201315. https:\/\/doi.org\/10.1159\/000442323.","journal-title":"Kidney Dis"},{"issue":"10","key":"2279_CR152","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.1681\/ASN.2014090903","volume":"26","author":"M Hilhorst","year":"2015","unstructured":"Hilhorst M, van Paassen P, Tervaert JWC. Proteinase 3-ANCA vasculitis versus myeloperoxidase-ANCA vasculitis. J Am Soc Nephrol. 2015;26(10):2314\u201327. https:\/\/doi.org\/10.1681\/ASN.2014090903.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"2279_CR153","doi-asserted-by":"publisher","DOI":"10.3390\/antib12010025","volume":"12","author":"M Paroli","year":"2023","unstructured":"Paroli M, Gioia C, Accapezzato D. New insights into pathogenesis and treatment of ANCA-associated vasculitis: autoantibodies and beyond. Antibodies. 2023;12(1):25. https:\/\/doi.org\/10.3390\/antib12010025.","journal-title":"Antibodies"},{"issue":"7","key":"2279_CR154","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1172\/JCI15918","volume":"110","author":"H Xiao","year":"2002","unstructured":"Xiao H, Heeringa P, Hu P, Liu Z, Zhao M, Aratani Y, et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest. 2002;110(7):955\u201363. https:\/\/doi.org\/10.1172\/JCI15918. PubMed PMID: 12370273; PubMedCentral PMCID: PMC151154.","journal-title":"J Clin Invest"},{"key":"2279_CR155","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.571933","volume":"12","author":"J Granel","year":"2021","unstructured":"Granel J, Korkmaz B, Nouar D, Weiss SAI, Jenne DE, Lemoine R, et al. Pathogenicity of proteinase 3-anti-neutrophil cytoplasmic antibody in granulomatosis with polyangiitis: implications as biomarker and future therapies. Front Immunol. 2021;12:571933. https:\/\/doi.org\/10.3389\/fimmu.2021.571933.","journal-title":"Front Immunol"},{"issue":"2","key":"2279_CR156","first-page":"335","volume":"141","author":"CO Savage","year":"1992","unstructured":"Savage CO, Pottinger BE, Gaskin G, Pusey CD, Pearson JD. Autoantibodies developing to myeloperoxidase and proteinase 3 in systemic vasculitis stimulate neutrophil cytotoxicity toward cultured endothelial cells. Am J Pathol. 1992;141(2):335\u201342.","journal-title":"Am J Pathol"},{"key":"2279_CR157","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109474","volume":"113","author":"C Wen","year":"2022","unstructured":"Wen C, Hu H, Yang W, Zhao Y, Zheng L, Jiang X, et al. Targeted inhibition of FcRn reduces NET formation to ameliorate experimental ulcerative colitis by accelerating ANCA clearance. Int Immunopharmacol. 2022;113:109474. https:\/\/doi.org\/10.1016\/j.intimp.2022.109474.","journal-title":"Int Immunopharmacol"},{"key":"2279_CR158","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.jdcr.2024.03.005","volume":"47","author":"A Ghafari-Saravi","year":"2024","unstructured":"Ghafari-Saravi A, Haussmann A, Wu J, Cheng K. Treatment of severe perinuclear antineutrophil cytoplasmic antibody\u2013associated vasculitis with efgartigimod. JAAD Case Rep. 2024;47:68\u201371. https:\/\/doi.org\/10.1016\/j.jdcr.2024.03.005.","journal-title":"JAAD Case Rep"},{"key":"2279_CR159","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1803537","author":"M Walsh","year":"2020","unstructured":"Walsh M, Merkel PA, Peh CA, Szpirt WM, Pu\u00e9chal X, Fujimoto S, et al. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N Engl J Med. 2020. https:\/\/doi.org\/10.1056\/NEJMoa1803537.","journal-title":"N Engl J Med"},{"issue":"7","key":"2279_CR160","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMoa2023386","volume":"384","author":"DRW Jayne","year":"2021","unstructured":"Jayne DRW, Merkel PA, Schall TJ, Bekker P, ADVOCATE Study Group. Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med. 2021;384(7):599\u2013609. https:\/\/doi.org\/10.1056\/NEJMoa2023386.","journal-title":"N Engl J Med"},{"issue":"10373","key":"2279_CR161","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/S0140-6736(22)01692-0","volume":"401","author":"ER Volkmann","year":"2023","unstructured":"Volkmann ER, Andr\u00e9asson K, Smith V. Systemic Sclerosis. Lancet (lond Engl). 2023;401(10373):304\u201318. https:\/\/doi.org\/10.1016\/S0140-6736(22)01692-0.","journal-title":"Lancet (lond Engl)"},{"key":"2279_CR162","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2025.100272","volume":"10","author":"A Chepy","year":"2025","unstructured":"Chepy A, Collet A, Launay D, Dubucquoi S, Sobanski V. Autoantibodies in Systemic Sclerosis: from disease bystanders to pathogenic players. J Transl Autoimmun. 2025;10:100272. https:\/\/doi.org\/10.1016\/j.jtauto.2025.100272.","journal-title":"J Transl Autoimmun"},{"key":"2279_CR163","doi-asserted-by":"publisher","unstructured":"Cavazzana I, Vojinovic T, Airo\u2019 P, Fredi M, Ceribelli A, Pedretti E, et al. Systemic sclerosis-specific antibodies: novel and classical biomarkers. Clin Rev Allergy Immunol. 2023;64(3):412\u201330. https:\/\/doi.org\/10.1007\/s12016-022-08946-w. PubMed PMID: 35716254; PubMed Central PMCID: PMC10167150.","DOI":"10.1007\/s12016-022-08946-w"},{"key":"2279_CR164","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.904631","volume":"13","author":"A Chepy","year":"2022","unstructured":"Chepy A, Vivier S, Bray F, Ternynck C, Meneboo JP, Figeac M, et al. Effects of Immunoglobulins G from Systemic Sclerosis patients in normal dermal fibroblasts: a multi-omics study. Front Immunol. 2022;13:904631. https:\/\/doi.org\/10.3389\/fimmu.2022.904631.","journal-title":"Front Immunol"},{"issue":"1","key":"2279_CR165","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-020-02360-3","volume":"22","author":"E Raschi","year":"2020","unstructured":"Raschi E, Privitera D, Bodio C, Lonati PA, Borghi MO, Ingegnoli F, et al. Scleroderma-specific autoantibodies embedded in immune complexes mediate endothelial damage: an early event in the pathogenesis of systemic Sclerosis. Arthritis Res Ther. 2020;22(1):265. https:\/\/doi.org\/10.1186\/s13075-020-02360-3.","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"2279_CR166","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/s41584-025-01240-x","volume":"21","author":"F Peyronel","year":"2025","unstructured":"Peyronel F, Della-Torre E, Maritati F, Urban ML, Bajema I, Schleinitz N, et al. IgG4-related disease and other fibro-inflammatory conditions. Nat Rev Rheumatol. 2025;21(5):275\u201390. https:\/\/doi.org\/10.1038\/s41584-025-01240-x.","journal-title":"Nat Rev Rheumatol"},{"issue":"8","key":"2279_CR167","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1136\/gutjnl-2015-310336","volume":"65","author":"M Shiokawa","year":"2016","unstructured":"Shiokawa M, Kodama Y, Kuriyama K, Yoshimura K, Tomono T, Morita T, et al. Pathogenicity of IgG in patients with IgG4-related disease. Gut. 2016;65(8):1322\u201332. https:\/\/doi.org\/10.1136\/gutjnl-2015-310336.","journal-title":"Gut"},{"issue":"1","key":"2279_CR168","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1136\/annrheumdis-2014-205233","volume":"74","author":"ZS Wallace","year":"2015","unstructured":"Wallace ZS, Mattoo H, Carruthers M, Mahajan VS, Della Torre E, Lee H, et al. Plasmablasts as a biomarker for IgG4-related disease, independent of serum IgG4 concentrations. Ann Rheum Dis. 2015;74(1):191\u20135. https:\/\/doi.org\/10.1136\/annrheumdis-2014-205233.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"2279_CR169","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/s41577-022-00821-1","volume":"23","author":"M Pyzik","year":"2023","unstructured":"Pyzik M, Kozicky LK, Gandhi AK, Blumberg RS. The therapeutic age of the neonatal Fc receptor. Nat Rev Immunol. 2023;23(7):415\u201332. https:\/\/doi.org\/10.1038\/s41577-022-00821-1.","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"2279_CR170","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.jaci.2020.07.016","volume":"146","author":"HH Peter","year":"2020","unstructured":"Peter HH, Ochs HD, Cunningham-Rundles C, Vinh DC, Kiessling P, Greve B, et al. Targeting FcRn for immunomodulation: benefits, risks, and practical considerations. J Allergy Clin Immunol. 2020;146(3):479-491.e5. https:\/\/doi.org\/10.1016\/j.jaci.2020.07.016.","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"2279_CR171","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s40263-023-01000-z","volume":"37","author":"YA Heo","year":"2023","unstructured":"Heo YA. Efgartigimod alfa in generalised Myasthenia Gravis: a profile of its use. CNS Drugs. 2023;37(5):467\u201373. https:\/\/doi.org\/10.1007\/s40263-023-01000-z.","journal-title":"CNS Drugs"},{"issue":"7","key":"2279_CR172","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","volume":"20","author":"JF Howard","year":"2021","unstructured":"Howard JF, Bril V, Vu T, Karam C, Peric S, Margania T, et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2021;20(7):526\u201336. https:\/\/doi.org\/10.1016\/S1474-4422(21)00159-9.","journal-title":"Lancet Neurol"},{"issue":"5","key":"2279_CR173","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S1474-4422(23)00077-7","volume":"22","author":"V Bril","year":"2023","unstructured":"Bril V, Dru\u017cd\u017c A, Grosskreutz J, Habib AA, Mantegazza R, Sacconi S, et al. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study. Lancet Neurol. 2023;22(5):383\u201394. https:\/\/doi.org\/10.1016\/S1474-4422(23)00077-7.","journal-title":"Lancet Neurol"},{"issue":"1","key":"2279_CR174","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/cpdd.1484","volume":"14","author":"A El Baghdady","year":"2025","unstructured":"El Baghdady A, Lled\u00f3-Garc\u00eda R, Gayfieva M, Lowcock R, Watanabe S, Sidhu J, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of the neonatal fc receptor inhibitor rozanolixizumab: an ethnic sensitivity study in healthy japanese, chinese, and white participants. Clin Pharmacol Drug Dev. 2025;14(1):26\u201335. https:\/\/doi.org\/10.1002\/cpdd.1484. PubMed PMID: 39569616; PubMedCentral PMCID: PMC11701949.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"2279_CR175","doi-asserted-by":"publisher","unstructured":"Gwathmey KG, Broome CM, Goebeler M, Murai H, Bata-Cs\u00f6rgo Z, Newland AC, et al. Safety profile of efgartigimod from global clinical trials across multiple immunoglobulin G-mediated autoimmune diseases. Expert Rev Clin Immunol [Internet]. 2025 May 4 [cited 2025 Aug 28]. Available from: https:\/\/www.tandfonline.com\/doi\/abs\/https:\/\/doi.org\/10.1080\/1744666X.2025.2497840.","DOI":"10.1080\/1744666X.2025.2497840"},{"issue":"1","key":"2279_CR176","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2025.2470542","volume":"21","author":"P Warang","year":"2025","unstructured":"Warang P, Singh G, Moshir M, Binazon O, Laghlali G, Chang LA, et al. Impact of FcRn antagonism on vaccine-induced protective immune responses against viral challenge in COVID-19 and influenza mouse vaccination models. Hum Vaccin Immunother. 2025;21(1):2470542. https:\/\/doi.org\/10.1080\/21645515.2025.2470542.","journal-title":"Hum Vaccin Immunother"},{"key":"2279_CR177","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.892534","volume":"13","author":"ES Ward","year":"2022","unstructured":"Ward ES, Gelinas D, Dreesen E, Van Santbergen J, Andersen JT, Silvestri NJ, et al. Clinical significance of serum albumin and implications of FcRn inhibitor treatment in IgG-mediated autoimmune disorders. Front Immunol. 2022;13:892534. https:\/\/doi.org\/10.3389\/fimmu.2022.892534.","journal-title":"Front Immunol"},{"key":"2279_CR178","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2024.1302714","volume":"18","author":"JH Leu","year":"2024","unstructured":"Leu JH, Vermeulen A, Abbes C, Arroyo S, Denney WS, Ling LE. Pharmacokinetics and pharmacodynamics across infusion rates of intravenously administered nipocalimab: results of a phase 1, placebo-controlled study. Front Neurosci. 2024;18:1302714. https:\/\/doi.org\/10.3389\/fnins.2024.1302714.","journal-title":"Front Neurosci"},{"issue":"2","key":"2279_CR179","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207937","volume":"102","author":"C Antozzi","year":"2024","unstructured":"Antozzi C, Guptill J, Bril V, Gamez J, Meuth SG, Nowak RJ, et al. Safety and efficacy of nipocalimab in patients with generalized myasthenia gravis: results from the randomized phase 2 vivacity-MG study. Neurology. 2024;102(2):e207937. https:\/\/doi.org\/10.1212\/WNL.0000000000207937.","journal-title":"Neurology"},{"key":"2279_CR180","doi-asserted-by":"publisher","unstructured":"Ma G, Crowley AR, Heyndrickx L, Rogiers I, Parthoens E, Van Santbergen J, et al. Differential effects of FcRn antagonists on the subcellular trafficking of FcRn and albumin. JCI Insight. 9(10):e176166. https:\/\/doi.org\/10.1172\/jci.insight.176166. PubMed PMID: 38713534; PubMed Central PMCID: PMC11141909.","DOI":"10.1172\/jci.insight.176166"},{"key":"2279_CR181","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00520","volume":"5","author":"G Vidarsson","year":"2014","unstructured":"Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol. 2014;5:520. https:\/\/doi.org\/10.3389\/fimmu.2014.00520.","journal-title":"Front Immunol"},{"issue":"4","key":"2279_CR182","doi-asserted-by":"publisher","first-page":"614","DOI":"10.4161\/mabs.24815","volume":"5","author":"C Passot","year":"2013","unstructured":"Passot C, Azzopardi N, Renault S, Baroukh N, Arnoult C, Ohresser M, et al. Influence of FCGRT gene polymorphisms on pharmacokinetics of therapeutic antibodies. MAbs. 2013;5(4):614\u20139. https:\/\/doi.org\/10.4161\/mabs.24815.","journal-title":"MAbs"},{"key":"2279_CR183","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01788","author":"A Recke","year":"2018","unstructured":"Recke A, Konitzer S, Lemcke S, Freitag M, Sommer NM, Abdelhady M, et al. The p.Arg435His variation of IgG3 with high affinity to FcRn is associated with susceptibility for Pemphigus vulgaris\u2014analysis of four different ethnic cohorts. Front Immunol. 2018. https:\/\/doi.org\/10.3389\/fimmu.2018.01788.","journal-title":"Front Immunol"},{"issue":"1","key":"2279_CR184","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2021.1882028","volume":"13","author":"TH Chu","year":"2021","unstructured":"Chu TH, Patz EF Jr, Ackerman ME. Coming together at the hinges: therapeutic prospects of IgG3. MAbs. 2021;13(1):1882028. https:\/\/doi.org\/10.1080\/19420862.2021.1882028.","journal-title":"MAbs"},{"key":"2279_CR185","doi-asserted-by":"publisher","DOI":"10.3390\/antib8040056","author":"VA Thomas","year":"2019","unstructured":"Thomas VA, Balthasar JP, Thomas VA, Balthasar JP. Understanding inter-individual variability in monoclonal antibody disposition. Antibodies. 2019. https:\/\/doi.org\/10.3390\/antib8040056.","journal-title":"Antibodies"},{"issue":"1","key":"2279_CR186","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11845-y","volume":"10","author":"CM Lanata","year":"2019","unstructured":"Lanata CM, Paranjpe I, Nititham J, Taylor KE, Gianfrancesco M, Paranjpe M, et al. A phenotypic and genomics approach in a multi-ethnic cohort to subtype systemic lupus erythematosus. Nat Commun. 2019;10(1):3902. https:\/\/doi.org\/10.1038\/s41467-019-11845-y.","journal-title":"Nat Commun"},{"issue":"suppl_1","key":"2279_CR187","doi-asserted-by":"publisher","first-page":"i67","DOI":"10.1093\/rheumatology\/kew399","volume":"56","author":"MJ Lewis","year":"2017","unstructured":"Lewis MJ, Jawad AS. The effect of ethnicity and genetic ancestry on the epidemiology, clinical features and outcome of systemic Lupus Erythematosus. Rheumatology Oxford. 2017;56(suppl_1):i67-77. https:\/\/doi.org\/10.1093\/rheumatology\/kew399.","journal-title":"Rheumatology Oxford"},{"issue":"9","key":"2279_CR188","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1007\/s10067-022-06296-8","volume":"41","author":"S Dubey","year":"2022","unstructured":"Dubey S, Adebajo AO. Crying out for equity: outcomes of rheumatic diseases confounded by ethnicity. Clin Rheumatol. 2022;41(9):2621\u20134. https:\/\/doi.org\/10.1007\/s10067-022-06296-8.","journal-title":"Clin Rheumatol"},{"issue":"2","key":"2279_CR189","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1002\/ajmg.c.31696","volume":"181","author":"YF Wang","year":"2019","unstructured":"Wang YF, Lau YL, Yang W. Genetic studies on systemic lupus erythematosus in East Asia point to population differences in disease susceptibility. Am J Med Genet C Semin Med Genet. 2019;181(2):262\u20138. https:\/\/doi.org\/10.1002\/ajmg.c.31696.","journal-title":"Am J Med Genet C Semin Med Genet"},{"issue":"6","key":"2279_CR190","doi-asserted-by":"publisher","first-page":"517","DOI":"10.18553\/jmcp.2024.30.6.517","volume":"30","author":"PW Lien","year":"2024","unstructured":"Lien PW, Joshi M, Tice JA, Agboola F, Nikitin D, Withanawasam V, et al. Cost-effectiveness of eculizumab and efgartigimod for the treatment of anti-acetylcholine receptor antibody-positive generalized myasthenia gravis. J Manag Care Spec Pharm. 2024;30(6):517\u201327. https:\/\/doi.org\/10.18553\/jmcp.2024.30.6.517.","journal-title":"J Manag Care Spec Pharm"},{"key":"2279_CR191","unstructured":"Efgartigimod alfa (vyvgart): CADTH reimbursement recommendation: indication: for the treatment of adult patients with generalized myasthenia gravis who are anti-acetylcholine receptor antibody positive [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 [cited 2025 Aug 28]. (CADTH Reimbursement Reviews and Recommendations). Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK602393\/. PubMed PMID: 38564544."},{"issue":"7_supplement_1","key":"2279_CR192","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000208162","volume":"102","author":"Z Siddiqi","year":"2024","unstructured":"Siddiqi Z, Genge A, Qi C, Zhou A, Kaprielian R, Locklin J, et al. Cost-effectiveness analysis of efgartigimod versus chronic intravenous immunoglobulin (IVIg) for treatment of acetylcholine receptor antibody positive (AChR-ab+) generalized Myasthenia Gravis (gMG) in Canada (P4-11.003). Neurology. 2024;102(7_supplement_1):6900. https:\/\/doi.org\/10.1212\/WNL.0000000000208162.","journal-title":"Neurology"},{"issue":"1","key":"2279_CR193","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15314","volume":"8","author":"SC Devanaboyina","year":"2017","unstructured":"Devanaboyina SC, Khare P, Challa DK, Ober RJ, Ward ES. Engineered clearing agents for the selective depletion of antigen-specific antibodies. Nat Commun. 2017;8(1):15314. https:\/\/doi.org\/10.1038\/ncomms15314.","journal-title":"Nat Commun"},{"issue":"3","key":"2279_CR194","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1016\/j.ymthe.2020.11.017","volume":"29","author":"W Sun","year":"2021","unstructured":"Sun W, Khare P, Wang X, Challa DK, Greenberg BM, Ober RJ, et al. Selective depletion of antigen-specific antibodies for the treatment of demyelinating disease. Mol Ther. 2021;29(3):1312\u201323. https:\/\/doi.org\/10.1016\/j.ymthe.2020.11.017.","journal-title":"Mol Ther"},{"key":"2279_CR195","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.115153","volume":"162","author":"D Shi","year":"2025","unstructured":"Shi D, Wu Y, Liang X, Xie S, Liang M, Lu T, et al. FcRn inhibition with efgartigimod ameliorates muscle weakness and modulates dendritic cell subsets in an experimental autoimmune myasthenia gravis mouse model. Int Immunopharmacol. 2025;162:115153. https:\/\/doi.org\/10.1016\/j.intimp.2025.115153.","journal-title":"Int Immunopharmacol"},{"issue":"5","key":"2279_CR196","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200455","volume":"12","author":"MC Tarasco","year":"2025","unstructured":"Tarasco MC, Rinaldi E, Frangiamore R, Vanoli F, Berni A, Iacomino N, et al. Unknown immunoregulatory effects of FcRn inhibition by efgartigimod in Myasthenia Gravis: a new mechanism of action beyond IgG reduction. Neurol Neuroimmunol Neuroinflamm. 2025;12(5):e200455. https:\/\/doi.org\/10.1212\/NXI.0000000000200455.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"1","key":"2279_CR197","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38063-x","volume":"14","author":"JA Ruffolo","year":"2023","unstructured":"Ruffolo JA, Chu LS, Mahajan SP, Gray JJ. Fast, accurate antibody structure prediction from deep learning on massive set of natural antibodies. Nat Commun. 2023;14(1):2389. https:\/\/doi.org\/10.1038\/s41467-023-38063-x.","journal-title":"Nat Commun"},{"issue":"9","key":"2279_CR198","doi-asserted-by":"publisher","first-page":"3876","DOI":"10.1016\/j.apsb.2024.06.015","volume":"14","author":"Y Zheng","year":"2024","unstructured":"Zheng Y, Luo S, Xu M, He Q, Xie J, Wu J, et al. Transepithelial transport of nanoparticles in oral drug delivery: from the perspective of surface and holistic property modulation. Acta Pharm Sin B. 2024;14(9):3876\u2013900. https:\/\/doi.org\/10.1016\/j.apsb.2024.06.015.","journal-title":"Acta Pharm Sin B"},{"key":"2279_CR199","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.jconrel.2024.01.015","volume":"366","author":"S Pinto","year":"2024","unstructured":"Pinto S, Hosseini M, Buckley ST, Yin W, Garousi J, Gr\u00e4slund T, et al. Nanoparticles targeting the intestinal Fc receptor enhance intestinal cellular trafficking of semaglutide. J Control Release. 2024;366:621\u201336. https:\/\/doi.org\/10.1016\/j.jconrel.2024.01.015.","journal-title":"J Control Release"},{"issue":"20","key":"2279_CR200","doi-asserted-by":"publisher","first-page":"10661","DOI":"10.1021\/acs.analchem.5c00486","volume":"97","author":"G Wu","year":"2025","unstructured":"Wu G, Xiang Y, Liu H, Hu C, Li Y, Feng J. Virtual screening combined with phase transition-FRET for discovery of small-molecule FcRn antagonists. Anal Chem. 2025;97(20):10661\u201370. https:\/\/doi.org\/10.1021\/acs.analchem.5c00486.","journal-title":"Anal Chem"},{"key":"2279_CR201","unstructured":"Woning SVD, Blanchetot C. Bispecific antigen binding construct [Internet]. US12071486B2, 2024 [cited 2025 Aug 28]. Available from: https:\/\/patents.google.com\/patent\/US12071486B2\/en."},{"key":"2279_CR202","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.891328","volume":"13","author":"WD Xu","year":"2022","unstructured":"Xu WD, Li R, Huang AF. Role of TL1A in inflammatory autoimmune diseases: a comprehensive review. Front Immunol. 2022;13:891328. https:\/\/doi.org\/10.3389\/fimmu.2022.891328.","journal-title":"Front Immunol"},{"issue":"7","key":"2279_CR203","doi-asserted-by":"publisher","first-page":"4033","DOI":"10.4049\/jimmunol.178.7.4033","volume":"178","author":"JL Prehn","year":"2007","unstructured":"Prehn JL, Thomas LS, Landers CJ, Yu QT, Michelsen KS, Targan SR. The T cell costimulator TL1A is induced by FcgammaR signaling in human monocytes and dendritic cells. J Immunol (baltim Md,: 1950). 2007;178(7):4033\u20138. https:\/\/doi.org\/10.4049\/jimmunol.178.7.4033.","journal-title":"J Immunol (baltim Md,: 1950)"},{"issue":"1","key":"2279_CR204","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.clim.2004.02.007","volume":"112","author":"JL Prehn","year":"2004","unstructured":"Prehn JL, Mehdizadeh S, Landers CJ, Luo X, Cha SC, Wei P, et al. Potential role for TL1A, the new TNF-family member and potent costimulator of IFN-\u03b3, in mucosal inflammation. Clin Immunol. 2004;112(1):66\u201377. https:\/\/doi.org\/10.1016\/j.clim.2004.02.007.","journal-title":"Clin Immunol"},{"issue":"5","key":"2279_CR205","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1016\/j.jaci.2025.02.018","volume":"155","author":"G Varricchi","year":"2025","unstructured":"Varricchi G, Poto R, Criscuolo G, Strisciuglio C, Nair P, Marone G. TL1A, a novel alarmin in airway, intestinal, and autoimmune disorders. J Allergy Clin Immunol. 2025;155(5):1420\u201334. https:\/\/doi.org\/10.1016\/j.jaci.2025.02.018.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"2279_CR206","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-75168-5","volume":"10","author":"N Jacob","year":"2020","unstructured":"Jacob N, Kumagai K, Abraham JP, Shimodaira Y, Ye Y, Luu J, et al. Direct signaling of TL1A-DR3 on fibroblasts induces intestinal fibrosis in vivo. Sci Rep. 2020;10(1):18189. https:\/\/doi.org\/10.1038\/s41598-020-75168-5.","journal-title":"Sci Rep"},{"key":"2279_CR207","doi-asserted-by":"crossref","unstructured":"Leach JL, Sedmak DD, Osborne JM, Rahill B, Lairmore MD, Anderson CL. Isolation from human placenta of the IgG transporter, FcRn, and localization to the syncytiotrophoblast: implications for maternal-fetal antibody transport. J Immunol (baltim Md,: 1950). 1996 Oct 15;157(8):3317\u201322. PubMed PMID: 8871627.","DOI":"10.4049\/jimmunol.157.8.3317"},{"issue":"7","key":"2279_CR208","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1016\/s0735-1097(98)00161-2","volume":"31","author":"JP Buyon","year":"1998","unstructured":"Buyon JP, Hiebert R, Copel J, Craft J, Friedman D, Katholi M, et al. Autoimmune-associated congenital heart block: demographics, mortality, morbidity and recurrence rates obtained from a national neonatal lupus registry. J Am Coll Cardiol. 1998;31(7):1658\u201366. https:\/\/doi.org\/10.1016\/s0735-1097(98)00161-2.","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"2279_CR209","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1172\/JCI27803","volume":"116","author":"RM Clancy","year":"2006","unstructured":"Clancy RM, Neufing PJ, Zheng P, O\u2019Mahony M, Nimmerjahn F, Gordon TP. Impaired clearance of apoptotic cardiocytes is linked to anti-SSA\/ro and -SSB\/La antibodies in the pathogenesis of congenital heart block. J Clin Invest. 2006;116(9):2413\u201322. https:\/\/doi.org\/10.1172\/JCI27803.","journal-title":"J Clin Invest"},{"issue":"3","key":"2279_CR210","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.jacc.2020.05.052","volume":"76","author":"JF Strasburger","year":"2020","unstructured":"Strasburger JF, Wacker-Gussmann A. Congenital heart block in subsequent pregnancies of SSA\/ro-positive mothers. J Am Coll Cardiol. 2020;76(3):303\u20135. https:\/\/doi.org\/10.1016\/j.jacc.2020.05.052.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"2279_CR211","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1056\/NEJMoa2314466","volume":"391","author":"KJ Moise","year":"2024","unstructured":"Moise KJ, Ling LE, Oepkes D, Tiblad E, Verweij EJTJ, Lopriore E, et al. Nipocalimab in early-onset severe hemolytic disease of the fetus and newborn. N Engl J Med. 2024;391(6):526\u201337. https:\/\/doi.org\/10.1056\/NEJMoa2314466.","journal-title":"N Engl J Med"},{"key":"2279_CR212","doi-asserted-by":"crossref","unstructured":"Tannenbaum SH, Finko R, Cines DB. Antibody and immune complexes induce tissue factor production by human endothelial cells. J Immunol (baltim Md,: 1950). 1986 Sep 1;137(5):1532\u20137. PubMed PMID: 3745915.","DOI":"10.4049\/jimmunol.137.5.1532"},{"issue":"11","key":"2279_CR213","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1056\/NEJMra1112830","volume":"368","author":"B Giannakopoulos","year":"2013","unstructured":"Giannakopoulos B, Krilis SA. The pathogenesis of the antiphospholipid syndrome. N Engl J Med. 2013;368(11):1033\u201344. https:\/\/doi.org\/10.1056\/NEJMra1112830.","journal-title":"N Engl J Med"}],"container-title":["Inflammation Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00011-026-02279-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00011-026-02279-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00011-026-02279-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T08:09:33Z","timestamp":1780906173000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00011-026-02279-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":213,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2279"],"URL":"https:\/\/doi.org\/10.1007\/s00011-026-02279-6","relation":{},"ISSN":["1420-908X"],"issn-type":[{"value":"1420-908X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,8]]},"assertion":[{"value":"11 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors report no declarations of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"134"}}